{"gene":"NOS2","run_date":"2026-06-10T05:19:52","timeline":{"discoveries":[{"year":1996,"finding":"The human NOS2 gene is transcriptionally activated by cytokines (TNFα, IL-1β, IFNγ), with multiple cytokine-responsive regions identified in the 5' flanking region at -3.8 to -5.8 kb, -5.8 to -7.0 kb, and -7.0 to -16 kb upstream of the transcription start site; the first 3.8 kb upstream showed no cytokine-inducible activity, in contrast to the murine macrophage NOS2 promoter.","method":"Nuclear run-on analysis; luciferase reporter constructs transfected into human liver epithelial cells (AKN-1); deletion analysis of NOS2 5' flanking region","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct promoter-reporter assays with deletion mapping and nuclear run-on in a defined cell system; multiple orthogonal methods in one study","pmids":["8577713"],"is_preprint":false},{"year":2007,"finding":"NOS2-derived NO S-nitrosylates NF-κB p65 at a conserved cysteine in the Rel homology domain, inhibiting NF-κB-dependent gene transcription; nuclear levels of S-nitrosylated p65 correlate with decreased p50-p65 heterodimer DNA binding and reduced NOS2 promoter occupancy, establishing a negative feedback loop whereby NOS2 limits its own expression.","method":"S-nitrosylation detection in cytokine-stimulated respiratory epithelial cells and macrophages; site-directed mutagenesis of p65 cysteine; NF-κB reporter assays; chromatin immunoprecipitation (ChIP) of NOS2 promoter","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — mutagenesis of critical cysteine, ChIP for promoter occupancy, and functional reporter assays in multiple cell types in one study","pmids":["17720813"],"is_preprint":false},{"year":2022,"finding":"LACC1 converts L-citrulline (the NOS2 reaction product) to L-ornithine and isocyanic acid, biochemically linking NOS2 to polyamine immunometabolism via ODC1; LACC1 phenotypes require upstream NOS2 and downstream ODC1 activity in inflammatory macrophages, demonstrated by genetic and chemical complementation.","method":"Biochemical enzyme assay; mouse genetic models (Lacc1-/-, Nos2-/-, Odc1 manipulation); bone marrow-derived macrophage infection with Salmonella; chemical complementation with L-ornithine","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — reconstituted enzyme activity, multiple knockout mouse models, chemical rescue, published in Nature with rigorous mechanistic validation","pmids":["35978195"],"is_preprint":false},{"year":2022,"finding":"NOS2 expression and associated NO signaling causes degradation of DNMT1 protein via an NO/p38-MAPK/KAT5-dependent mechanism, leading to global DNA hypomethylation, LINE-1 retrotransposon activation, and epithelial transformation in human cell lines.","method":"NOS2 overexpression in human cell lines; DNMT1 protein stability assays; p38-MAPK inhibition; KAT5 manipulation; bisulfite sequencing for methylation; LINE-1 expression and DNA damage assays","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — mechanistic pathway (NO→p38-MAPK→KAT5→DNMT1 degradation→hypomethylation) validated with multiple orthogonal methods and inhibitor experiments in one study","pmids":["35584114"],"is_preprint":false},{"year":2013,"finding":"Induction and stability of human Th17 cells requires endogenous NOS2 activity within CD4+ T cells and the downstream canonical cGMP–cGK signaling pathway; NOS2 inhibition or cGMP-cGK blockade abolished de novo Th17 induction and selectively suppressed IL-17 production by established Th17 cells.","method":"NOS2 inhibition; cGMP-cGK pathway inhibition; differentiation of naive, memory, and tumor-infiltrating CD4+ T cells in vitro; cytokine measurement; patient-derived MDSCs and OvCa specimens","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — pharmacological and pathway inhibition experiments with human primary cells, multiple cell types, replicated across naive/memory/TIL subsets","pmids":["23797095"],"is_preprint":false},{"year":2016,"finding":"In TLR4-activated microglia, Sur1-Trpm4 channels regulate Ca2+-sensitive calcineurin/NFAT signaling, which controls NOS2 transcription; inhibition or gene silencing of Sur1-Trpm4 reduces NFAT nuclear translocation and Nos2 upregulation, as confirmed by chromatin immunoprecipitation showing NFAT binding to the Nos2 promoter.","method":"Pharmacological inhibition of Sur1 (glibenclamide) and Trpm4 (9-phenanthrol); gene silencing of Abcc8 and Trpm4; calcium imaging; patch clamp; ChIP for NFAT at Nos2 promoter; qPCR; Griess assay for NO; primary microglia and N9 cell line; knockout mice (Abcc8-/-, Trpm4-/-)","journal":"Journal of neuroinflammation","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — ChIP validation of NFAT-Nos2 promoter binding, electrophysiology, calcium imaging, genetic knockouts, and pharmacological confirmation in multiple systems","pmids":["27246103"],"is_preprint":false},{"year":2017,"finding":"NO produced by NOS2 induces COX2 expression via TRAF2 activation (TNFα-dependent in MDA-MB-468 cells; TNFα-independent but ER-stress-dependent in MDA-MB-231 cells), while PGE2 (the COX2 product) induces NOS2 protein, establishing a feed-forward NOS2/COX2 crosstalk loop in triple-negative breast cancer cells.","method":"NOS2 and COX2 inhibition (aminoguanidine, aspirin/indomethacin); TRAF2 activity assays; TNFα neutralization; ER stress pathway analysis; xenograft tumor growth experiments; protein expression by Western blot","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — mechanistic pathway dissection with inhibitors, neutralizing antibodies, and in vivo xenograft validation across two TNBC cell lines","pmids":["29087320"],"is_preprint":false},{"year":2000,"finding":"α-MSH inhibits LPS+IFNγ-induced NOS2 gene transcription in macrophages primarily by suppressing C/EBPβ (but not NF-κB) DNA-binding activity; deletion or mutation of the C/EBP box in the NOS2 promoter abolishes α-MSH's inhibitory effect, demonstrating that C/EBPβ is a required transcriptional activator of NOS2.","method":"Gel shift (EMSA) and supershift assays; NOS2 promoter-luciferase transfection with C/EBP box deletion/mutation constructs; RAW 264.7 macrophages","journal":"Kidney international","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — promoter mutagenesis combined with EMSA supershift identifying the specific transcription factor binding site required for NOS2 transcription","pmids":["10844594"],"is_preprint":false},{"year":2017,"finding":"Epigenetic regulation of Nos2 expression by the NLRC4 inflammasome requires caspase-1-mediated cleavage of PARP1 (ARTD1), which increases chromatin accessibility at NF-κB binding sites in the Nos2 promoter; caspase-1 acts downstream of NF-κB activation and is required for Nos2 transcription and NO-dependent macrophage resistance to Salmonella.","method":"Cytosolic flagellin stimulation; caspase-1 inhibition/knockout; NF-κB activation assays; PARP1 cleavage assays; chromatin accessibility assays; Salmonella infection of macrophages","journal":"Scientific reports","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — mechanistic epistasis (caspase-1 downstream of NF-κB) established by genetic and pharmacological dissection with chromatin accessibility readout and functional infection outcome","pmids":["28150715"],"is_preprint":false},{"year":2002,"finding":"Rho GTPase signaling through ROCK suppresses NOS2 production downstream of promoter activity, at the mRNA and protein level; statin-mediated HMG-CoA reductase inhibition increases cytokine-dependent NOS2 promoter activity via geranylgeranylation-dependent prenylation events independent of the Rho/ROCK pathway.","method":"ROCK inhibitor (Y-27632); statin treatment; geranylgeranyl pyrophosphate rescue; NOS2 promoter-luciferase assays; mRNA and protein level measurements in human alveolar epithelial cells","journal":"American journal of physiology. Lung cellular and molecular physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — promoter assays combined with protein/mRNA level measurements and pharmacological pathway dissection in a single lab study","pmids":["12169580"],"is_preprint":false},{"year":2001,"finding":"An S714P missense mutation in NOS2 from Dahl/Rapp salt-sensitive rats reduces NOS2 protein half-life (demonstrated by metabolic labeling) without affecting steady-state mRNA levels, decreasing nitrite production in a manner dependent on L-arginine concentration; a proteasomal post-translational degradation mechanism is implicated.","method":"Transient transfection of wild-type, S714P, and S714A NOS2 mutants into COS-7 cells; metabolic labeling to measure protein half-life; immunoblot; nitrite production assay with varying L-arginine concentrations","journal":"Circulation research","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro mutagenesis reconstitution with metabolic labeling establishing post-translational protein stability as the mechanism; single lab but rigorous methods","pmids":["11509447"],"is_preprint":false},{"year":1999,"finding":"The pentanucleotide (CCTTT)n repeat within the NOS2A promoter functions as a transcriptional regulatory element; different repeat lengths confer different levels of IL-1β-inducible NOS2 promoter activity, with the 14-repeat allele showing the greatest induction in a luciferase reporter assay, and high-glucose conditions inhibit induction.","method":"Luciferase reporter gene assay with (CCTTT)n constructs of varying repeat length transfected into colonic carcinoma cells; IL-1β stimulation; high-glucose conditions","journal":"FASEB journal","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — direct promoter-reporter functional assay; single lab, single method but with systematic allele series","pmids":["10506586"],"is_preprint":false},{"year":2019,"finding":"Tristetraprolin (TTP), encoded by Zfp36, directly binds AU-rich elements in the Nos2 3' UTR and suppresses Nos2 expression in intestinal epithelial cells; TTP knockout (Zfp36ΔIEC) mice show elevated Nos2 expression in the colonic epithelium and reduced susceptibility to DSS-induced colitis.","method":"Cre-lox conditional epithelial Zfp36 knockout mice; RNA-sequencing; TTP-Nos2 3'UTR interaction assay; DSS colitis model","journal":"Scientific reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic knockout with cell-type-specific Cre, RNA-seq identification, direct 3'UTR binding assay, and in vivo functional phenotype","pmids":["31595002"],"is_preprint":false},{"year":2023,"finding":"BRD4 regulates glycolysis-dependent stabilization of Nos2 mRNA in macrophages upon H. pylori infection; BRD4 is recruited to promoters of glycolytic genes (Slc2a1, Hk2) via HIF-1α to support glycolysis, and BRD4-mediated glycolysis stabilizes Nos2 mRNA for NO production needed to kill H. pylori; Brd4-deficient macrophages show impaired glycolysis, reduced iNOS expression, and increased bacterial colonization.","method":"Brd4 myeloid-specific conditional knockout (Brd4-CKO) mice; RNA sequencing; ChIP of BRD4 at glycolytic gene promoters; glycolysis assays; NO/killing assays; pyruvate rescue; in vivo H. pylori infection model","journal":"Cellular and molecular gastroenterology and hepatology","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — conditional genetic knockout, ChIP, metabolic rescue, and in vivo infection model together establish the HIF-1α→BRD4→glycolysis→Nos2 mRNA stabilization pathway","pmids":["37820788"],"is_preprint":false},{"year":2014,"finding":"NOS2 expression and NO production in the tumor microenvironment is induced by hypoxia, serum withdrawal, IFNγ, and exogenous NO in ER-negative breast cancer cells, consistent with a feed-forward regulation; NOS2 inhibition suppresses markers of aggressive phenotype (S100A8, IL-6, IL-8, TIMP-1), reduces cellular migration, increases chemosensitivity to Taxol, and suppresses tumor xenograft growth and brain metastasis.","method":"NOS2 inhibition in MDA-MB-231 cells; stimulation with hypoxia, serum withdrawal, IFNγ, and NO donors; marker expression assays; migration assay; Taxol chemoresistance assay; nude mouse xenograft and fat-pad-to-brain metastasis model","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple stimuli tested, pharmacological inhibition with defined phenotypic readouts, and in vivo xenograft/metastasis validation","pmids":["24733928"],"is_preprint":false},{"year":2018,"finding":"Mannan-induced NOS2 expression in macrophages drives IL-1α release from skin macrophages, which promotes IL-17 production by innate lymphoid cells and psoriatic arthritis pathogenesis; genetic deletion or pharmacological inhibition of Nos2 suppresses disease, and NOS2 expression is upregulated in monocytes from PsA patients.","method":"Nos2 knockout mice in mannan-induced psoriasis/PsA model; NOS inhibitor (L-NAME); IL-1α measurement; innate lymphoid cell IL-17 assay; patient monocyte NOS2 expression","journal":"Science advances","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic knockout and pharmacological inhibition establishing NOS2→IL-1α→IL-17 pathway in disease model, corroborated by human patient data","pmids":["29774240"],"is_preprint":false},{"year":2020,"finding":"Inherited autosomal recessive NOS2 deficiency (homozygous frameshift mutation producing a truncated, NO-inactive NOS2 protein) in a human patient was associated with fatal CMV infection, establishing that NOS2 is required for control of CMV in humans; the patient was otherwise resistant to other common pathogens, suggesting NOS2 is redundant for control of most infections.","method":"Whole-exome sequencing; experimental testing of mutant NOS2 alleles for NO production; functional assays of truncated NOS2 protein","journal":"The New England journal of medicine","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — human genetic loss-of-function with experimental validation of NO-null truncated protein, unique clinical case establishing essential non-redundant role in CMV immunity","pmids":["31995689"],"is_preprint":false},{"year":2015,"finding":"NOS2-derived NO downregulates tight junction protein ZO-1 expression at the transcriptional level in human lung epithelial cells; NOS2-/- mice show attenuated inflammatory response to bleomycin-induced injury with reduced NF-κB DNA-binding activity and a shift toward alternative macrophage activation.","method":"NOS2 inhibitor 1400W via osmotic pump; NOS2-/- mice; bleomycin instillation model; NF-κB DNA-binding activity assay; BAL analysis; ZO-1 mRNA and protein measurement; macrophage activation markers","journal":"Free radical biology & medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological inhibition and genetic knockout with mechanistic readouts in both in vivo and cell-based models, single lab","pmids":["26526764"],"is_preprint":false},{"year":2006,"finding":"TLR4-mediated cardiomyocyte survival requires both MyD88 (the TLR4 adaptor) and NOS2; genetic deletion or pharmacological inhibition of NOS2 abolishes LPS-induced survival and functional rescue (Ca2+ transients, cell shortening) of cardiomyocytes under serum deprivation-induced apoptosis, placing NOS2 downstream of MyD88 in the TLR4 survival pathway.","method":"TLR4-/-, MyD88-/-, and pharmacological NOS2 inhibition in isolated cardiomyocytes; serum deprivation apoptosis model; TUNEL assay; DNA laddering; DNA-histone ELISA; Ca2+ transients; cell shortening measurements","journal":"American journal of physiology. Heart and circulatory physiology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis (TLR4→MyD88→NOS2) confirmed by multiple knockout lines with orthogonal apoptosis and function readouts","pmids":["16648192"],"is_preprint":false},{"year":1998,"finding":"NOS2-derived NO mediates decreases in some cytochrome P450 catalytic activities (testosterone 6β-hydroxylase, 15α- and 16β-hydroxylase) during endotoxemia, as demonstrated by absence of these activity decreases in NOS2 knockout mice or aminoguanidine-treated mice; however, LPS-induced decreases in CYP2C29, CYP3A11 mRNA and CYP2E1, CYP2C-like, CYP3A-like protein levels occur independently of NOS2/NO.","method":"NOS2 knockout mice; aminoguanidine NOS inhibitor; LPS-induced endotoxemia model; cytochrome P450 mRNA and protein expression; testosterone hydroxylase activity assays","journal":"Molecular pharmacology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic knockout and pharmacological inhibition with enzymatic activity assays distinguish NO-dependent from NO-independent P450 regulation","pmids":["9687568"],"is_preprint":false},{"year":2010,"finding":"NOD1 (but not TLR4) is the dominant pathway for NOS2 induction in vascular smooth muscle cells; NOD1-mediated NOS2 induction requires Rip2 kinase (inhibited by PP2) whereas TLR4-mediated macrophage NOS2 induction requires caspase activity and PKC; both pathways converge on NF-κB and MAPK signaling.","method":"Pharmacological inhibitors (SC-514 for NF-κB, SB203580/PD98059 for MAPK, z-VAD-fmk for caspase, Gö6976 for PKC, PP2 for Rip2); NOD1 agonist FK565; LPS for TLR4; NOS2 protein expression and NO production in vascular smooth muscle cells vs. macrophages","journal":"British journal of pharmacology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — systematic pharmacological pathway dissection in two cell types, single lab study","pmids":["20649597"],"is_preprint":false},{"year":2015,"finding":"IL-17 intensifies IFNγ-induced NOS2 upregulation in RAW 264.7 macrophages by further activating STAT1 phosphorylation (Y701) and NF-κB nuclear translocation; IL-17 enhances p38 MAPK phosphorylation and limits ERK1/2 phosphorylation, thereby augmenting NF-κB pathway activity and NOS2 transcription. ChIP confirmed enhanced STAT1 and NF-κB binding to the NOS2 promoter.","method":"Western blot for STAT1, NF-κB, p38 MAPK, ERK1/2 phosphorylation; ChIP assay for STAT1 and NF-κB at NOS2 promoter; STAT1 and NF-κB inhibitors; colorimetric NO assay; qPCR","journal":"International journal of molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP plus inhibitor experiments establish transcription factor contributions to NOS2 promoter; single lab","pmids":["26677135"],"is_preprint":false},{"year":2004,"finding":"Manganese potentiates LPS-induced NOS2 expression in C6 glioma cells through mitochondrial ROS production, which activates NF-κB (via NIK-mediated IκBα phosphorylation); overexpression of dominant-negative IκBα or NIK mutant, or scavenging mitochondrial ROS with MitoQ, attenuates Mn-enhanced NOS2 expression.","method":"Overexpression of mutant IκBα (S32/36A) and dominant-negative NIK; MitoQ mitochondrial antioxidant; gel shift for NF-κB p65/p50; mitochondrial membrane potential and calcium assays; ROS measurement; NOS2 protein and NO assays","journal":"Brain research. Molecular brain research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — dominant-negative constructs and organelle-specific antioxidant establish the mitochondrial ROS→NIK→NF-κB→NOS2 pathway; single lab","pmids":["15010209"],"is_preprint":false},{"year":2020,"finding":"DNA-based probes targeting phagosomal NO demonstrate that single-stranded RNA of bacterial origin acts as a PAMP that activates NOS2 in microglia phagosomes by engaging TLR-7; this PAMP-TLR7 interaction triggers rapid phagosomal NOS2 activity, mapped in live zebrafish brains.","method":"DNA-based ratiometric NO probes delivered to phagosomes and endosomes; live zebrafish brain imaging; TLR-7 activation; microglia phagosomal NO measurement","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — novel direct real-time imaging of NOS2 activity in phagosomes linked to specific PAMP-TLR7 interaction; single study, technically innovative","pmids":["32554491"],"is_preprint":false},{"year":2014,"finding":"NOS2 expression is restricted to scattered neurons in specific brain regions (piriform and entorhinal cortex, amygdala, thalamus, hypothalamus, dentate gyrus, cerebellum) in the healthy brain, but inflammation (intracerebral LPS + IFNγ) triggers transient NOS2 expression in microglia rather than neurons; NOS2 expression is rarely detected in microglia under non-inflammatory conditions.","method":"Transgenic mouse expressing tdTomato and CRE recombinase under Nos2 regulatory regions (lineage tracing); immunohistochemistry; intracerebral LPS + IFNγ injection","journal":"Glia","confidence":"High","confidence_rationale":"Tier 2 / Strong — purpose-built lineage-tracing transgenic mouse providing reliable cell-type-specific NOS2 expression mapping under basal and inflammatory conditions","pmids":["24615726"],"is_preprint":false},{"year":2004,"finding":"NOS2 promotes apoptosis in acute cardiac allograft rejection via p53-dependent mechanisms; NOS2-deficient recipients show reduced p53 transcript levels, increased Bcl-2/Bax ratio, decreased Bcl-Xl, lower caspase-1 and -3 activity, and fewer TUNEL-positive nuclei; Fas/FasL and TNFα/TNFR1 pathways are not altered by NOS2 deficiency.","method":"NOS2 knockout recipient mice in heterotopic cardiac transplant model; TUNEL assay; antinucleosome ELISA; 32P-RT-PCR for caspase-1/-3, p53, Bcl-2, Bax, Bcl-Xl; DEVD-pNA caspase-3 activity; PARP cleavage","journal":"Circulation","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal apoptosis assays combined with genetic epistasis in knockout mice establishing NOS2→p53→Bax/Bcl-2 apoptotic pathway","pmids":["9989972"],"is_preprint":false}],"current_model":"NOS2 (inducible nitric oxide synthase) is a cytokine- and pathogen-inducible enzyme that synthesizes NO from L-arginine (with L-citrulline as co-product); its transcription is controlled by multiple upstream regulators including NF-κB, STAT1, C/EBPβ, NFAT (via Sur1-Trpm4/Ca2+ signaling), caspase-1/PARP1 epigenetic remodeling, BRD4-mediated glycolysis, and post-transcriptional suppression by TTP binding to Nos2 3'UTR, while NOS2-derived NO exerts negative feedback by S-nitrosylating NF-κB p65; the enzyme functions in inflammatory macrophages upstream of LACC1 (converting its citrulline product to ornithine for polyamine metabolism), promotes Th17 differentiation via cGMP-cGK signaling, drives apoptosis in tissue rejection via p53 activation, mediates epigenetic transformation through DNMT1 degradation via p38-MAPK/KAT5, regulates cytochrome P450 catalytic activities, and is essential for anti-CMV immunity in humans."},"narrative":{"mechanistic_narrative":"NOS2 (inducible nitric oxide synthase) is a cytokine- and pathogen-inducible enzyme that synthesizes nitric oxide (NO) from L-arginine to drive inflammatory, immunometabolic, and tissue-remodeling programs [PMID:8577713, PMID:35978195]. Its expression is normally absent or low and is induced transcriptionally by pro-inflammatory cytokines (TNFα, IL-1β, IFNγ) acting through distal 5' regulatory regions of the human gene [PMID:8577713], with C/EBPβ identified as a required promoter-binding activator [PMID:10844594] and STAT1 and NF-κB cooperating to amplify induction, for example when IL-17 augments IFNγ signaling [PMID:26677135]. Diverse upstream inputs converge on this control: NOD1/Rip2 and TLR4 signaling [PMID:20649597], TLR7-sensed bacterial RNA in microglial phagosomes [PMID:32554491], NLRC4/caspase-1-mediated PARP1 cleavage that opens chromatin at NF-κB sites [PMID:28150715], Sur1-Trpm4/Ca2+/calcineurin-NFAT signaling [PMID:27246103], and HIF-1α/BRD4-driven glycolysis that stabilizes Nos2 mRNA [PMID:37820788]; conversely, tristetraprolin binds AU-rich elements in the Nos2 3'UTR to suppress its expression [PMID:31595002], and NOS2-derived NO S-nitrosylates NF-κB p65 to reduce NOS2 promoter occupancy, forming a negative-feedback loop [PMID:17720813]. Downstream, NOS2 acts as a hub of inflammatory effector functions: its L-citrulline product is channeled by LACC1 to ornithine and polyamine immunometabolism via ODC1 in macrophages [PMID:35978195], its NO supports antibacterial killing and Th17 induction through cGMP-cGK signaling [PMID:23797095, PMID:37820788], and it links to a feed-forward NOS2/COX2 loop and aggressive phenotypes in breast cancer [PMID:29087320, PMID:24733928]. NO further drives p53-dependent apoptosis in cardiac allograft rejection [PMID:9989972] and NO/p38-MAPK/KAT5-mediated DNMT1 degradation causing DNA hypomethylation and epithelial transformation [PMID:35584114]. Inherited autosomal recessive NOS2 deficiency in humans causes fatal CMV infection while sparing control of most other pathogens, defining a non-redundant role in anti-CMV immunity [PMID:31995689].","teleology":[{"year":1996,"claim":"Established that the human NOS2 gene is transcriptionally inducible by inflammatory cytokines and mapped the responsive elements to distal upstream regions, distinguishing human regulation from the murine macrophage promoter.","evidence":"Nuclear run-on and deletion-mapped luciferase reporters in human liver epithelial cells stimulated with TNFα/IL-1β/IFNγ","pmids":["8577713"],"confidence":"High","gaps":["Did not identify the specific transcription factors binding the distal regions","Functional relevance in immune cell types not addressed"]},{"year":1998,"claim":"Defined a downstream consequence of NOS2 activity by showing NO selectively suppresses specific cytochrome P450 catalytic activities during endotoxemia, separating NO-dependent from NO-independent P450 regulation.","evidence":"NOS2 knockout mice and aminoguanidine in an LPS endotoxemia model with P450 activity and expression assays","pmids":["9687568"],"confidence":"High","gaps":["Molecular mechanism of NO action on P450 enzymes not resolved","Limited to a subset of P450 isoforms"]},{"year":1999,"claim":"Identified a cis-acting polymorphic element by showing the promoter (CCTTT)n pentanucleotide repeat modulates IL-1β-inducible NOS2 transcription in an allele-length-dependent manner.","evidence":"Luciferase reporter assays with varying (CCTTT)n repeat constructs in colonic carcinoma cells","pmids":["10506586"],"confidence":"Medium","gaps":["Single cell line, single reporter method","Trans-acting factor binding the repeat not identified"]},{"year":2000,"claim":"Identified C/EBPβ as a required transcriptional activator of NOS2 and a target of anti-inflammatory α-MSH, defining a specific factor distinct from NF-κB.","evidence":"EMSA/supershift and promoter-luciferase assays with C/EBP box deletion/mutation in RAW 264.7 macrophages","pmids":["10844594"],"confidence":"High","gaps":["How α-MSH signaling reaches C/EBPβ DNA binding not detailed","Macrophage cell line only"]},{"year":2001,"claim":"Demonstrated post-translational control of NOS2 abundance by showing an S714P mutation shortens protein half-life without affecting mRNA, implicating proteasomal degradation.","evidence":"Mutant NOS2 transfection in COS-7 cells with metabolic labeling and nitrite assays","pmids":["11509447"],"confidence":"High","gaps":["Specific degradation machinery (E3 ligase) not identified","Findings derived from a rat salt-sensitive allele in a heterologous cell line"]},{"year":2004,"claim":"Connected NOS2 to apoptotic tissue injury by showing NO drives p53-dependent apoptosis during cardiac allograft rejection independently of Fas and TNF pathways.","evidence":"NOS2 knockout recipients in a heterotopic cardiac transplant model with multiple apoptosis readouts","pmids":["9989972"],"confidence":"High","gaps":["Direct molecular link between NO and p53 induction not defined","Cell type executing apoptosis not specified"]},{"year":2004,"claim":"Showed NOS2 induction can be amplified by mitochondrial ROS via the NIK/NF-κB axis, broadening the upstream signals controlling NOS2.","evidence":"Dominant-negative IκBα/NIK and mitochondrial antioxidant MitoQ with NF-κB gel shifts in C6 glioma cells","pmids":["15010209"],"confidence":"Medium","gaps":["Single cell line and stimulus (manganese)","Physiological relevance beyond metal exposure unclear"]},{"year":2006,"claim":"Placed NOS2 downstream of TLR4/MyD88 as a pro-survival effector in cardiomyocytes, expanding NOS2 function beyond cytotoxic inflammation.","evidence":"TLR4-/-, MyD88-/- and NOS2 inhibition in isolated cardiomyocytes under serum deprivation apoptosis","pmids":["16648192"],"confidence":"High","gaps":["Downstream survival signaling from NO not mapped","Context dependence of pro-survival vs pro-apoptotic NO unresolved"]},{"year":2007,"claim":"Revealed a negative-feedback mechanism by which NOS2-derived NO S-nitrosylates NF-κB p65 to reduce NOS2 promoter occupancy, allowing the enzyme to limit its own induction.","evidence":"p65 cysteine mutagenesis, S-nitrosylation detection, NF-κB reporters and NOS2 promoter ChIP in epithelial cells and macrophages","pmids":["17720813"],"confidence":"High","gaps":["Quantitative contribution of feedback to physiological NO output not established","Other S-nitrosylation targets in the pathway not assessed"]},{"year":2010,"claim":"Distinguished cell-type-specific upstream pathways, identifying NOD1/Rip2 as dominant for NOS2 induction in vascular smooth muscle versus TLR4/caspase/PKC in macrophages, both converging on NF-κB/MAPK.","evidence":"Systematic pharmacological inhibitor dissection in vascular smooth muscle cells versus macrophages","pmids":["20649597"],"confidence":"Medium","gaps":["Inhibitor-based, no genetic confirmation","Single lab, two cell types"]},{"year":2013,"claim":"Defined an effector role for NOS2 in adaptive immunity by showing endogenous NOS2 and downstream cGMP-cGK signaling are required for human Th17 induction and stability.","evidence":"NOS2 and cGMP-cGK pathway inhibition in human naive, memory, and tumor-infiltrating CD4+ T cells","pmids":["23797095"],"confidence":"High","gaps":["Molecular targets of cGK driving IL-17 not identified","Mainly pharmacological inhibition"]},{"year":2014,"claim":"Mapped basal versus inflammatory NOS2-expressing cell types in brain, showing scattered neuronal expression at baseline and inducible microglial expression under inflammation.","evidence":"Nos2 promoter-driven lineage-tracing transgenic mice with immunohistochemistry under basal and LPS+IFNγ conditions","pmids":["24615726"],"confidence":"High","gaps":["Functional role of basal neuronal NOS2 not addressed","Mouse data only"]},{"year":2014,"claim":"Established NOS2 as a driver of aggressive tumor phenotype, with NO induced by hypoxia/IFNγ and feed-forward NO promoting migration, chemoresistance, and metastasis in ER-negative breast cancer.","evidence":"NOS2 inhibition with multiple stimuli and in vivo xenograft/brain metastasis models in MDA-MB-231 cells","pmids":["24733928"],"confidence":"High","gaps":["Direct molecular targets of NO driving each phenotype not fully resolved","Cell-line-restricted models"]},{"year":2015,"claim":"Showed NO regulates epithelial barrier integrity and inflammatory tone by transcriptionally downregulating ZO-1 and shaping macrophage polarization and NF-κB activity in lung injury.","evidence":"NOS2 inhibitor and NOS2-/- mice in a bleomycin lung injury model with ZO-1 and NF-κB readouts","pmids":["26526764"],"confidence":"Medium","gaps":["Mechanism linking NO to ZO-1 transcription unresolved","Single lab"]},{"year":2015,"claim":"Showed IL-17 cooperates with IFNγ to intensify NOS2 transcription by enhancing STAT1 phosphorylation and NF-κB binding at the NOS2 promoter.","evidence":"Phospho-signaling Western blots, NOS2 promoter ChIP, and inhibitors in RAW 264.7 macrophages","pmids":["26677135"],"confidence":"Medium","gaps":["Single cell line","Relative contributions of STAT1 vs NF-κB not quantified"]},{"year":2016,"claim":"Identified Sur1-Trpm4/Ca2+-calcineurin-NFAT signaling as an upstream controller of Nos2 transcription in TLR4-activated microglia.","evidence":"Pharmacology, gene silencing, calcium imaging, patch clamp, knockout mice, and NFAT ChIP at the Nos2 promoter","pmids":["27246103"],"confidence":"High","gaps":["Interaction with canonical NF-κB control not integrated","Restricted to microglial context"]},{"year":2017,"claim":"Defined a feed-forward NOS2/COX2 crosstalk loop in triple-negative breast cancer, with NO inducing COX2 via TRAF2 and PGE2 inducing NOS2.","evidence":"Enzyme inhibitors, TRAF2 assays, ER-stress analysis, and xenografts across two TNBC cell lines","pmids":["29087320"],"confidence":"High","gaps":["Generalizability beyond TNBC cell lines unclear","Quantitative loop dynamics not modeled"]},{"year":2017,"claim":"Uncovered an epigenetic mechanism of NOS2 induction in which NLRC4/caspase-1-mediated PARP1 cleavage increases chromatin accessibility at NF-κB sites in the Nos2 promoter, placing caspase-1 downstream of NF-κB.","evidence":"Cytosolic flagellin stimulation, caspase-1 perturbation, PARP1 cleavage and chromatin accessibility assays with Salmonella infection","pmids":["28150715"],"confidence":"High","gaps":["Direct demonstration that PARP1 cleavage product drives accessibility not fully isolated","Limited to inflammasome-activating contexts"]},{"year":2018,"claim":"Linked macrophage NOS2 to autoinflammatory disease by showing NOS2 drives IL-1α release and downstream IL-17 from innate lymphoid cells in psoriatic arthritis.","evidence":"Nos2 knockout mice and NOS inhibition in a mannan-induced PsA model corroborated by patient monocyte data","pmids":["29774240"],"confidence":"High","gaps":["Mechanism connecting NO to IL-1α release not defined","Model-specific induction"]},{"year":2019,"claim":"Identified post-transcriptional restraint of NOS2 by showing tristetraprolin binds the Nos2 3'UTR to suppress epithelial expression, tuning colitis susceptibility.","evidence":"Epithelial-specific Zfp36 knockout mice, RNA-seq, 3'UTR binding assay, and DSS colitis model","pmids":["31595002"],"confidence":"High","gaps":["Interplay with transcriptional induction not quantified","Restricted to intestinal epithelium"]},{"year":2020,"claim":"Defined the essential, non-redundant role of NOS2 in human anti-CMV immunity through a patient with inherited NO-null NOS2 deficiency and fatal CMV infection.","evidence":"Whole-exome sequencing and functional NO-production testing of a truncated mutant NOS2 allele","pmids":["31995689"],"confidence":"High","gaps":["Single patient","Cellular mechanism by which NO controls CMV not defined"]},{"year":2020,"claim":"Demonstrated phagosomal NOS2 activation in microglia triggered by bacterial single-stranded RNA engaging TLR7, using real-time NO imaging.","evidence":"DNA-based ratiometric NO probes in live zebrafish brain phagosomes with TLR7 activation","pmids":["32554491"],"confidence":"Medium","gaps":["Mechanistic coupling of TLR7 to phagosomal NOS2 not detailed","Single technically novel study"]},{"year":2022,"claim":"Connected NOS2 enzymatic output to immunometabolism by showing LACC1 converts the citrulline product to ornithine feeding ODC1-dependent polyamine metabolism in inflammatory macrophages.","evidence":"Reconstituted enzyme assay, multiple knockout mice (Lacc1, Nos2, Odc1), Salmonella infection, and ornithine chemical rescue","pmids":["35978195"],"confidence":"High","gaps":["Flux contribution relative to other citrulline fates not quantified","Human in vivo relevance not addressed"]},{"year":2022,"claim":"Revealed an oncogenic epigenetic mechanism in which NOS2/NO drives DNMT1 degradation via p38-MAPK/KAT5, causing DNA hypomethylation, LINE-1 activation, and epithelial transformation.","evidence":"NOS2 overexpression, DNMT1 stability assays, p38/KAT5 manipulation, bisulfite sequencing, and LINE-1 readouts in human cell lines","pmids":["35584114"],"confidence":"High","gaps":["In vivo tumorigenesis validation limited","Step linking NO to p38-MAPK activation not detailed"]},{"year":2023,"claim":"Established a metabolic-epigenetic axis controlling NOS2 mRNA stability, in which HIF-1α-recruited BRD4 supports glycolysis that stabilizes Nos2 mRNA for antibacterial NO production.","evidence":"Myeloid Brd4 conditional knockout mice, RNA-seq, BRD4 ChIP at glycolytic genes, glycolysis/NO assays, pyruvate rescue, and in vivo H. pylori infection","pmids":["37820788"],"confidence":"High","gaps":["Direct RNA-stabilizing factor linking glycolysis to Nos2 mRNA not identified","Restricted to H. pylori macrophage context"]},{"year":null,"claim":"How the many parallel transcriptional, post-transcriptional, metabolic, and post-translational inputs are quantitatively integrated to set NOS2 output in a given cell type, and how NO output is matched to specific effector outcomes, remains unresolved.","evidence":"No single study integrates the multiple convergent regulatory layers captured in the timeline","pmids":[],"confidence":"Low","gaps":["No unified quantitative model of NOS2 regulation across cell types","Cell-type-specific determinants of pro-survival vs cytotoxic vs oncogenic NO not defined","Structural and catalytic regulation of the human enzyme not addressed in this corpus"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016491","term_label":"oxidoreductase activity","supporting_discovery_ids":[2,16]},{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[0,16]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[10,23]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[2,4,13,16]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[0,1,7,8,5]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[2,13]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[25,18]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[3,8]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[18,20]}],"complexes":[],"partners":["LACC1","RELA","CEBPB","STAT1","PARP1","DNMT1","TRAF2","ZFP36"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P35228","full_name":"Nitric oxide synthase, inducible","aliases":["Hepatocyte NOS","HEP-NOS","Inducible NO synthase","Inducible NOS","iNOS","NOS type II","Peptidyl-cysteine S-nitrosylase NOS2"],"length_aa":1153,"mass_kda":131.1,"function":"Produces nitric oxide (NO) which is a messenger molecule with diverse functions throughout the body (PubMed:7504305, PubMed:7531687, PubMed:7544004, PubMed:7682706). In macrophages, NO mediates tumoricidal and bactericidal actions. Also has nitrosylase activity and mediates cysteine S-nitrosylation of cytoplasmic target proteins such PTGS2/COX2 (By similarity). As component of the iNOS-S100A8/9 transnitrosylase complex involved in the selective inflammatory stimulus-dependent S-nitrosylation of GAPDH on 'Cys-247' implicated in regulation of the GAIT complex activity and probably multiple targets including ANXA5, EZR, MSN and VIM (PubMed:25417112). Involved in inflammation, enhances the synthesis of pro-inflammatory mediators such as IL6 and IL8 (PubMed:19688109)","subcellular_location":"Cytoplasm, cytosol","url":"https://www.uniprot.org/uniprotkb/P35228/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/NOS2","classification":"Not Classified","n_dependent_lines":2,"n_total_lines":1208,"dependency_fraction":0.0016556291390728477},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/NOS2","total_profiled":1310},"omim":[{"mim_id":"611162","title":"MALARIA, SUSCEPTIBILITY TO","url":"https://www.omim.org/entry/611162"},{"mim_id":"608228","title":"NANOS C2HC-TYPE ZINC FINGER 2; NANOS2","url":"https://www.omim.org/entry/608228"},{"mim_id":"608212","title":"IMMUNITY-RELATED GTPase M; IRGM","url":"https://www.omim.org/entry/608212"},{"mim_id":"605692","title":"TRANSIENT RECEPTOR POTENTIAL CATION CHANNEL, SUBFAMILY M, MEMBER 7; TRPM7","url":"https://www.omim.org/entry/605692"},{"mim_id":"604702","title":"HMG BOX DOMAIN-CONTAINING 4; HMGXB4","url":"https://www.omim.org/entry/604702"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Group enriched","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"intestine","ntpm":19.6},{"tissue":"lymphoid tissue","ntpm":13.8}],"url":"https://www.proteinatlas.org/search/NOS2"},"hgnc":{"alias_symbol":["iNOS","NOS","HEP-NOS"],"prev_symbol":["NOS2A"]},"alphafold":{"accession":"P35228","domains":[{"cath_id":"3.40.50.360","chopping":"521-699","consensus_level":"high","plddt":85.7696,"start":521,"end":699},{"cath_id":"1.20.990.10","chopping":"707-713_780-809_824-899","consensus_level":"high","plddt":90.5057,"start":707,"end":899},{"cath_id":"2.40.30.10","chopping":"733-778_906-965","consensus_level":"medium","plddt":90.9233,"start":733,"end":965},{"cath_id":"3.40.50.80","chopping":"971-1133","consensus_level":"high","plddt":90.6331,"start":971,"end":1133}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P35228","model_url":"https://alphafold.ebi.ac.uk/files/AF-P35228-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P35228-F1-predicted_aligned_error_v6.png","plddt_mean":85.38},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=NOS2","jax_strain_url":"https://www.jax.org/strain/search?query=NOS2"},"sequence":{"accession":"P35228","fasta_url":"https://rest.uniprot.org/uniprotkb/P35228.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P35228/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P35228"}},"corpus_meta":[{"pmid":"8577713","id":"PMC_8577713","title":"Transcriptional regulation of human inducible nitric oxide synthase (NOS2) gene by cytokines: initial analysis of the human NOS2 promoter.","date":"1996","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/8577713","citation_count":347,"is_preprint":false},{"pmid":"10518502","id":"PMC_10518502","title":"nos-1 and nos-2, two genes related to Drosophila nanos, regulate primordial germ cell development and survival in Caenorhabditis elegans.","date":"1999","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/10518502","citation_count":278,"is_preprint":false},{"pmid":"17720813","id":"PMC_17720813","title":"NOS2 regulation of NF-kappaB by S-nitrosylation of p65.","date":"2007","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17720813","citation_count":195,"is_preprint":false},{"pmid":"24733928","id":"PMC_24733928","title":"Tumor microenvironment-based feed-forward regulation of NOS2 in breast cancer progression.","date":"2014","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/24733928","citation_count":146,"is_preprint":false},{"pmid":"10593859","id":"PMC_10593859","title":"Regulation of the expression of the inflammatory nitric oxide synthase (NOS2) by cyclic AMP.","date":"1999","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/10593859","citation_count":134,"is_preprint":false},{"pmid":"19906966","id":"PMC_19906966","title":"NOS2 gene deficiency protects from sepsis-induced long-term cognitive deficits.","date":"2009","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/19906966","citation_count":121,"is_preprint":false},{"pmid":"10506586","id":"PMC_10506586","title":"Genotyping and functional analysis of a polymorphic (CCTTT)(n) repeat of NOS2A in diabetic retinopathy.","date":"1999","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/10506586","citation_count":121,"is_preprint":false},{"pmid":"10072717","id":"PMC_10072717","title":"Expression of cardiac cytokines and inducible form of nitric oxide synthase (NOS2) in Trypanosoma cruzi-infected mice.","date":"1999","source":"Journal of molecular and cellular cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/10072717","citation_count":111,"is_preprint":false},{"pmid":"26117324","id":"PMC_26117324","title":"Signaling and stress: The redox landscape in NOS2 biology.","date":"2015","source":"Free radical biology & medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26117324","citation_count":105,"is_preprint":false},{"pmid":"23797095","id":"PMC_23797095","title":"Induction and stability of human Th17 cells require endogenous NOS2 and cGMP-dependent NO signaling.","date":"2013","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/23797095","citation_count":98,"is_preprint":false},{"pmid":"12972406","id":"PMC_12972406","title":"Multiple contributing roles for NOS2 in LPS-induced acute airway inflammation in mice.","date":"2003","source":"American journal of physiology. Lung cellular and molecular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/12972406","citation_count":91,"is_preprint":false},{"pmid":"29087320","id":"PMC_29087320","title":"Coexpression of NOS2 and COX2 accelerates tumor growth and reduces survival in estrogen receptor-negative breast cancer.","date":"2017","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/29087320","citation_count":88,"is_preprint":false},{"pmid":"19096157","id":"PMC_19096157","title":"The effects of NOS2 gene deletion on mice expressing mutated human AbetaPP.","date":"2008","source":"Journal of Alzheimer's disease : JAD","url":"https://pubmed.ncbi.nlm.nih.gov/19096157","citation_count":84,"is_preprint":false},{"pmid":"29805307","id":"PMC_29805307","title":"PM2.5 induces autophagy-mediated cell death via NOS2 signaling in human bronchial epithelium cells.","date":"2018","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/29805307","citation_count":76,"is_preprint":false},{"pmid":"28276497","id":"PMC_28276497","title":"Leishmania (Leishmania) amazonensis induces macrophage miR-294 and miR-721 expression and modulates infection by targeting NOS2 and L-arginine metabolism.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28276497","citation_count":75,"is_preprint":false},{"pmid":"9687568","id":"PMC_9687568","title":"Down-regulation of cytochrome P450 mRNAs and proteins in mice lacking a functional NOS2 gene.","date":"1998","source":"Molecular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/9687568","citation_count":74,"is_preprint":false},{"pmid":"16499902","id":"PMC_16499902","title":"Translational repression restricts expression of the C. elegans Nanos homolog NOS-2 to the embryonic germline.","date":"2006","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/16499902","citation_count":74,"is_preprint":false},{"pmid":"9989972","id":"PMC_9989972","title":"Attenuated acute cardiac rejection in NOS2 -/- recipients correlates with reduced apoptosis.","date":"1999","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/9989972","citation_count":74,"is_preprint":false},{"pmid":"26806087","id":"PMC_26806087","title":"Dermatomyositis With or Without Anti-Melanoma Differentiation-Associated Gene 5 Antibodies: Common Interferon Signature but Distinct NOS2 Expression.","date":"2016","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/26806087","citation_count":73,"is_preprint":false},{"pmid":"27246103","id":"PMC_27246103","title":"The Sur1-Trpm4 channel regulates NOS2 transcription in TLR4-activated microglia.","date":"2016","source":"Journal of neuroinflammation","url":"https://pubmed.ncbi.nlm.nih.gov/27246103","citation_count":72,"is_preprint":false},{"pmid":"19575238","id":"PMC_19575238","title":"NOS2A, TLR4, and IFNGR1 interactions influence pulmonary tuberculosis susceptibility in African-Americans.","date":"2009","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19575238","citation_count":69,"is_preprint":false},{"pmid":"28506076","id":"PMC_28506076","title":"NOS2 as an Emergent Player in Progression of Cancer.","date":"2017","source":"Antioxidants & redox signaling","url":"https://pubmed.ncbi.nlm.nih.gov/28506076","citation_count":68,"is_preprint":false},{"pmid":"16648192","id":"PMC_16648192","title":"MyD88 and NOS2 are essential for toll-like receptor 4-mediated survival effect in cardiomyocytes.","date":"2006","source":"American journal of physiology. Heart and circulatory physiology","url":"https://pubmed.ncbi.nlm.nih.gov/16648192","citation_count":62,"is_preprint":false},{"pmid":"19501636","id":"PMC_19501636","title":"Comparative analysis of zebrafish nos2a and nos2b genes.","date":"2009","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/19501636","citation_count":60,"is_preprint":false},{"pmid":"15010209","id":"PMC_15010209","title":"Manganese potentiates lipopolysaccharide-induced expression of NOS2 in C6 glioma cells through mitochondrial-dependent activation of nuclear factor kappaB.","date":"2004","source":"Brain research. Molecular brain research","url":"https://pubmed.ncbi.nlm.nih.gov/15010209","citation_count":59,"is_preprint":false},{"pmid":"35978195","id":"PMC_35978195","title":"LACC1 bridges NOS2 and polyamine metabolism in inflammatory macrophages.","date":"2022","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/35978195","citation_count":56,"is_preprint":false},{"pmid":"22618808","id":"PMC_22618808","title":"NOS2 enhances KRAS-induced lung carcinogenesis, inflammation and microRNA-21 expression.","date":"2012","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/22618808","citation_count":56,"is_preprint":false},{"pmid":"15174013","id":"PMC_15174013","title":"Linkage and association with the NOS2A locus on chromosome 17q11 in multiple sclerosis.","date":"2004","source":"Annals of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/15174013","citation_count":52,"is_preprint":false},{"pmid":"12552317","id":"PMC_12552317","title":"Nucleotide and haplotypic diversity of the NOS2A promoter region and its relationship to cerebral malaria.","date":"2003","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/12552317","citation_count":51,"is_preprint":false},{"pmid":"9811327","id":"PMC_9811327","title":"NOS2 mediates opposing effects in models of acute and chronic cardiac rejection: insights from NOS2-knockout mice.","date":"1998","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/9811327","citation_count":45,"is_preprint":false},{"pmid":"10944422","id":"PMC_10944422","title":"Survey of the allelic frequency of a NOS2A promoter microsatellite in human populations: assessment of the NOS2A gene and predisposition to infectious disease.","date":"2000","source":"Nitric oxide : biology and chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10944422","citation_count":45,"is_preprint":false},{"pmid":"12169580","id":"PMC_12169580","title":"Mechanisms of NOS2 regulation by Rho GTPase signaling in airway epithelial cells.","date":"2002","source":"American journal of physiology. Lung cellular and molecular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/12169580","citation_count":45,"is_preprint":false},{"pmid":"17955236","id":"PMC_17955236","title":"Influence of the inducible nitric oxide synthase gene (NOS2A) on inflammatory bowel disease susceptibility.","date":"2007","source":"Immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/17955236","citation_count":44,"is_preprint":false},{"pmid":"11880293","id":"PMC_11880293","title":"Pattern of NOS2 and NOS3 mRNA expression in human A549 cells and primary cultured AEC II.","date":"2002","source":"American journal of physiology. Lung cellular and molecular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/11880293","citation_count":43,"is_preprint":false},{"pmid":"17561811","id":"PMC_17561811","title":"Inhibition of spinal constitutive NOS-2 by 1400W attenuates tissue injury and inflammation-induced hyperalgesia and spinal p38 activation.","date":"2007","source":"The European journal of neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/17561811","citation_count":41,"is_preprint":false},{"pmid":"18820242","id":"PMC_18820242","title":"Novel noncoding antisense RNA transcribed from human anti-NOS2A locus is differentially regulated during neuronal differentiation of embryonic stem cells.","date":"2008","source":"RNA (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/18820242","citation_count":40,"is_preprint":false},{"pmid":"14551604","id":"PMC_14551604","title":"Haplotypic relationship between SNP and microsatellite markers at the NOS2A locus in two populations.","date":"2003","source":"Genes and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/14551604","citation_count":40,"is_preprint":false},{"pmid":"24615726","id":"PMC_24615726","title":"NOS2 expression is restricted to neurons in the healthy brain but is triggered in microglia upon inflammation.","date":"2014","source":"Glia","url":"https://pubmed.ncbi.nlm.nih.gov/24615726","citation_count":40,"is_preprint":false},{"pmid":"31995689","id":"PMC_31995689","title":"Fatal Cytomegalovirus Infection in an Adult with Inherited NOS2 Deficiency.","date":"2020","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31995689","citation_count":40,"is_preprint":false},{"pmid":"22715033","id":"PMC_22715033","title":"NOS-2 signaling and cancer therapy.","date":"2012","source":"IUBMB life","url":"https://pubmed.ncbi.nlm.nih.gov/22715033","citation_count":39,"is_preprint":false},{"pmid":"19723394","id":"PMC_19723394","title":"Association of SLC11A1 with tuberculosis and interactions with NOS2A and TLR2 in African-Americans and Caucasians.","date":"2009","source":"The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease","url":"https://pubmed.ncbi.nlm.nih.gov/19723394","citation_count":38,"is_preprint":false},{"pmid":"30227679","id":"PMC_30227679","title":"Involvement of NOS2 Activity on Human Glioma Cell Growth, Clonogenic Potential, and Neurosphere Generation.","date":"2018","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/30227679","citation_count":38,"is_preprint":false},{"pmid":"29774240","id":"PMC_29774240","title":"Mannan-induced Nos2 in macrophages enhances IL-17-driven psoriatic arthritis by innate lymphocytes.","date":"2018","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/29774240","citation_count":38,"is_preprint":false},{"pmid":"15512981","id":"PMC_15512981","title":"Blocking CD200-CD200 receptor axis augments NOS-2 expression and aggravates experimental autoimmune uveoretinitis in Lewis rats.","date":"2004","source":"Ocular immunology and inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/15512981","citation_count":38,"is_preprint":false},{"pmid":"11692109","id":"PMC_11692109","title":"(CCTTT)n repeat polymorphism in the NOS2 gene promoter is associated with atopy.","date":"2001","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/11692109","citation_count":38,"is_preprint":false},{"pmid":"19041302","id":"PMC_19041302","title":"Peripheral antinociceptive effects of mu- and delta-opioid receptor agonists in NOS2 and NOS1 knockout mice during chronic inflammatory pain.","date":"2008","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/19041302","citation_count":37,"is_preprint":false},{"pmid":"30152521","id":"PMC_30152521","title":"Understanding the tumour micro-environment communication network from an NOS2/COX2 perspective.","date":"2018","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/30152521","citation_count":36,"is_preprint":false},{"pmid":"24035972","id":"PMC_24035972","title":"Zinc ferrite nanoparticles activate IL-1b, NFKB1, CCL21 and NOS2 signaling to induce mitochondrial dependent intrinsic apoptotic pathway in WISH cells.","date":"2013","source":"Toxicology and applied pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/24035972","citation_count":36,"is_preprint":false},{"pmid":"26526764","id":"PMC_26526764","title":"Role of NOS2 in pulmonary injury and repair in response to bleomycin.","date":"2015","source":"Free radical biology & medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26526764","citation_count":35,"is_preprint":false},{"pmid":"28424427","id":"PMC_28424427","title":"NOS2 expression in glioma cell lines and glioma primary cell cultures: correlation with neurosphere generation and SOX-2 expression.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28424427","citation_count":35,"is_preprint":false},{"pmid":"22258388","id":"PMC_22258388","title":"Association of NOS2 and potential effect of VEGF, IL6, CCL2 and IL1RN polymorphisms and haplotypes on susceptibility to GCA--a simultaneous study of 130 potentially functional SNPs in 14 candidate genes.","date":"2012","source":"Rheumatology (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/22258388","citation_count":35,"is_preprint":false},{"pmid":"16771678","id":"PMC_16771678","title":"Effects of noradrenaline on neuronal NOS2 expression and viability.","date":"2006","source":"Antioxidants & redox signaling","url":"https://pubmed.ncbi.nlm.nih.gov/16771678","citation_count":34,"is_preprint":false},{"pmid":"32554491","id":"PMC_32554491","title":"DNA-based fluorescent probes of NOS2 activity in live brains.","date":"2020","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/32554491","citation_count":33,"is_preprint":false},{"pmid":"7558036","id":"PMC_7558036","title":"Three members of the nitric oxide synthase II gene family (NOS2A, NOS2B, and NOS2C) colocalize to human chromosome 17.","date":"1995","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/7558036","citation_count":33,"is_preprint":false},{"pmid":"31999809","id":"PMC_31999809","title":"MyD88-dependent influx of monocytes and neutrophils impairs lymph node B cell responses to chikungunya virus infection via Irf5, Nos2 and Nox2.","date":"2020","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/31999809","citation_count":33,"is_preprint":false},{"pmid":"31226744","id":"PMC_31226744","title":"NOS2 inhibitor 1400W Induces Autophagic Flux and Influences Extracellular Vesicle Profile in Human Glioblastoma U87MG Cell Line.","date":"2019","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/31226744","citation_count":32,"is_preprint":false},{"pmid":"16823855","id":"PMC_16823855","title":"NOS2A and the modulating effect of cigarette smoking in Parkinson's disease.","date":"2006","source":"Annals of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/16823855","citation_count":31,"is_preprint":false},{"pmid":"30949455","id":"PMC_30949455","title":"Melatonin and Leishmania amazonensis Infection Altered miR-294, miR-30e, and miR-302d Impacting on Tnf, Mcp-1, and Nos2 Expression.","date":"2019","source":"Frontiers in cellular and infection microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/30949455","citation_count":30,"is_preprint":false},{"pmid":"16771677","id":"PMC_16771677","title":"Beta-amyloid-dependent expression of NOS2 in neurons: prevention by an alpha2-adrenergic antagonist.","date":"2006","source":"Antioxidants & redox signaling","url":"https://pubmed.ncbi.nlm.nih.gov/16771677","citation_count":30,"is_preprint":false},{"pmid":"16574921","id":"PMC_16574921","title":"Association analysis of common variants of ELN, NOS2A, APOE and ACE2 to intracranial aneurysm.","date":"2006","source":"Stroke","url":"https://pubmed.ncbi.nlm.nih.gov/16574921","citation_count":28,"is_preprint":false},{"pmid":"25003233","id":"PMC_25003233","title":"mNos2 deletion and human NOS2 replacement in Alzheimer disease models.","date":"2014","source":"Journal of neuropathology and experimental neurology","url":"https://pubmed.ncbi.nlm.nih.gov/25003233","citation_count":28,"is_preprint":false},{"pmid":"27192959","id":"PMC_27192959","title":"Association of NOS2 and NOS3 gene polymorphisms with susceptibility to type 2 diabetes mellitus and diabetic nephropathy in the Chinese Han population.","date":"2016","source":"IUBMB life","url":"https://pubmed.ncbi.nlm.nih.gov/27192959","citation_count":28,"is_preprint":false},{"pmid":"15565661","id":"PMC_15565661","title":"PGE1-induced NO reduces apoptosis by D-galactosamine through attenuation of NF-kappaB and NOS-2 expression in rat hepatocytes.","date":"2004","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/15565661","citation_count":28,"is_preprint":false},{"pmid":"32862202","id":"PMC_32862202","title":"Heme oxygenase-1 inhibition promotes IFNγ- and NOS2-mediated control of Mycobacterium tuberculosis infection.","date":"2020","source":"Mucosal immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32862202","citation_count":27,"is_preprint":false},{"pmid":"22174044","id":"PMC_22174044","title":"Gene deletion of nos2 protects against manganese-induced neurological dysfunction in juvenile mice.","date":"2011","source":"Toxicological sciences : an official journal of the Society of Toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/22174044","citation_count":27,"is_preprint":false},{"pmid":"28244985","id":"PMC_28244985","title":"High BMI levels associate with reduced mRNA expression of IL10 and increased mRNA expression of iNOS (NOS2) in human frontal cortex.","date":"2017","source":"Translational psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/28244985","citation_count":26,"is_preprint":false},{"pmid":"28150715","id":"PMC_28150715","title":"Epigenetic regulation of nitric oxide synthase 2, inducible (Nos2) by NLRC4 inflammasomes involves PARP1 cleavage.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28150715","citation_count":26,"is_preprint":false},{"pmid":"35584114","id":"PMC_35584114","title":"NOS2 and S-nitrosothiol signaling induces DNA hypomethylation and LINE-1 retrotransposon expression.","date":"2022","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/35584114","citation_count":25,"is_preprint":false},{"pmid":"25870319","id":"PMC_25870319","title":"NOS-2 Inhibition in Phosgene-Induced Acute Lung Injury.","date":"2015","source":"Toxicological sciences : an official journal of the Society of Toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/25870319","citation_count":25,"is_preprint":false},{"pmid":"27397579","id":"PMC_27397579","title":"Macrophage NOS2 in Tumor Leukocytes.","date":"2016","source":"Antioxidants & redox signaling","url":"https://pubmed.ncbi.nlm.nih.gov/27397579","citation_count":24,"is_preprint":false},{"pmid":"35740092","id":"PMC_35740092","title":"The Breast Cancer Protooncogenes HER2, BRCA1 and BRCA2 and Their Regulation by the iNOS/NOS2 Axis.","date":"2022","source":"Antioxidants (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/35740092","citation_count":23,"is_preprint":false},{"pmid":"10844594","id":"PMC_10844594","title":"alpha-MSH inhibits induction of C/EBPbeta-DNA binding activity and NOS2 gene transcription in macrophages.","date":"2000","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/10844594","citation_count":23,"is_preprint":false},{"pmid":"22368302","id":"PMC_22368302","title":"Single nucleotide polymorphisms in the NOS2 and NOS3 genes are associated with exhaled nitric oxide.","date":"2012","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/22368302","citation_count":23,"is_preprint":false},{"pmid":"10674474","id":"PMC_10674474","title":"The CCTTT polymorphism in the NOS2A gene is associated with dementia with Lewy bodies.","date":"2000","source":"Neuroreport","url":"https://pubmed.ncbi.nlm.nih.gov/10674474","citation_count":21,"is_preprint":false},{"pmid":"20649597","id":"PMC_20649597","title":"Nucleotide oligomerization domain 1 is a dominant pathway for NOS2 induction in vascular smooth muscle cells: comparison with Toll-like receptor 4 responses in macrophages.","date":"2010","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/20649597","citation_count":21,"is_preprint":false},{"pmid":"38892290","id":"PMC_38892290","title":"NOS2 and COX-2 Co-Expression Promotes Cancer Progression: A Potential Target for Developing Agents to Prevent or Treat Highly Aggressive Breast Cancer.","date":"2024","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/38892290","citation_count":20,"is_preprint":false},{"pmid":"37820788","id":"PMC_37820788","title":"BRD4 Regulates Glycolysis-Dependent Nos2 Expression in Macrophages Upon H pylori Infection.","date":"2023","source":"Cellular and molecular gastroenterology and hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/37820788","citation_count":20,"is_preprint":false},{"pmid":"36375380","id":"PMC_36375380","title":"Systemic Nos2 Depletion and Cox inhibition limits TNBC disease progression and alters lymphoid cell spatial orientation and density.","date":"2022","source":"Redox biology","url":"https://pubmed.ncbi.nlm.nih.gov/36375380","citation_count":20,"is_preprint":false},{"pmid":"11509447","id":"PMC_11509447","title":"Nitric oxide synthase (NOS2) mutation in Dahl/Rapp rats decreases enzyme stability.","date":"2001","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/11509447","citation_count":20,"is_preprint":false},{"pmid":"16771679","id":"PMC_16771679","title":"Characterization of NO and cytokine production in immune-activated microglia and peritoneal macrophages derived from a mouse model expressing the human NOS2 gene on a mouse NOS2 knockout background.","date":"2006","source":"Antioxidants & redox signaling","url":"https://pubmed.ncbi.nlm.nih.gov/16771679","citation_count":20,"is_preprint":false},{"pmid":"15158332","id":"PMC_15158332","title":"Simultaneous abrogation of NOS-2 and COX-2 activities is lethal in partially hepatectomised mice.","date":"2004","source":"Journal of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/15158332","citation_count":20,"is_preprint":false},{"pmid":"19859740","id":"PMC_19859740","title":"Malaria severity and human nitric oxide synthase type 2 (NOS2) promoter haplotypes.","date":"2009","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19859740","citation_count":20,"is_preprint":false},{"pmid":"18714530","id":"PMC_18714530","title":"(CCTTT)n polymorphism of NOS2A in nasal polyposis and asthma: a case-control study.","date":"2008","source":"Journal of investigational allergology & clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/18714530","citation_count":19,"is_preprint":false},{"pmid":"12563676","id":"PMC_12563676","title":"Effect of NOS2 gene deficiency on the development of autoantibody mediated arthritis and subsequent articular cartilage degeneration.","date":"2003","source":"The Journal of rheumatology","url":"https://pubmed.ncbi.nlm.nih.gov/12563676","citation_count":19,"is_preprint":false},{"pmid":"31595002","id":"PMC_31595002","title":"Tristetraprolin targets Nos2 expression in the colonic epithelium.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/31595002","citation_count":18,"is_preprint":false},{"pmid":"10462376","id":"PMC_10462376","title":"Abnormal regulation of aortic NOS2 and NOS3 activity and expression from portal vein-stenosed rats after lipopolysaccharide administration.","date":"1999","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/10462376","citation_count":18,"is_preprint":false},{"pmid":"20374233","id":"PMC_20374233","title":"Analysis of single nucleotide polymorphisms in the NOS2A gene and interaction with smoking in age-related macular degeneration.","date":"2010","source":"Annals of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/20374233","citation_count":16,"is_preprint":false},{"pmid":"23826716","id":"PMC_23826716","title":"Association analysis of nitric oxide synthases: NOS1, NOS2A and NOS3 genes, with multiple sclerosis.","date":"2013","source":"Annals of human biology","url":"https://pubmed.ncbi.nlm.nih.gov/23826716","citation_count":16,"is_preprint":false},{"pmid":"31015500","id":"PMC_31015500","title":"Mice lacking Casp1, Ifngr and Nos2 genes exhibit altered depressive- and anxiety-like behaviour, and gut microbiome composition.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/31015500","citation_count":16,"is_preprint":false},{"pmid":"16703578","id":"PMC_16703578","title":"Lack of association between NOS2 pentanucleotide repeat polymorphism and asthma phenotypes or exhaled nitric oxide concentration.","date":"2006","source":"Pediatric pulmonology","url":"https://pubmed.ncbi.nlm.nih.gov/16703578","citation_count":16,"is_preprint":false},{"pmid":"24465666","id":"PMC_24465666","title":"NOS2 is critical to the development of emphysema in Sftpd deficient mice but does not affect surfactant homeostasis.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24465666","citation_count":16,"is_preprint":false},{"pmid":"26677135","id":"PMC_26677135","title":"IL-17 intensifies IFN-γ-induced NOS2 upregulation in RAW 264.7 cells by further activating STAT1 and NF-κB.","date":"2015","source":"International journal of molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26677135","citation_count":16,"is_preprint":false},{"pmid":"27737359","id":"PMC_27737359","title":"Analysis of polymorphisms in Interleukin 10, NOS2A, and ESR2 genes in chronic and aggressive periodontitis.","date":"2016","source":"Brazilian oral research","url":"https://pubmed.ncbi.nlm.nih.gov/27737359","citation_count":15,"is_preprint":false},{"pmid":"14985675","id":"PMC_14985675","title":"Inducible nitric oxide synthase gene (NOS2A) haplotypes and the outcome of hepatitis C virus infection.","date":"2004","source":"Genes and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/14985675","citation_count":15,"is_preprint":false},{"pmid":"26664124","id":"PMC_26664124","title":"The role of NOS2A -954G/C and vascular endothelial growth factor +936C/T polymorphisms in type 2 diabetes mellitus and diabetic nonproliferative retinopathy risk management.","date":"2015","source":"Therapeutics and clinical risk management","url":"https://pubmed.ncbi.nlm.nih.gov/26664124","citation_count":15,"is_preprint":false},{"pmid":"37169743","id":"PMC_37169743","title":"Interferon-gamma is quintessential for NOS2 and COX2 expression in ER- breast tumors that lead to poor outcome.","date":"2023","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/37169743","citation_count":14,"is_preprint":false},{"pmid":"12736741","id":"PMC_12736741","title":"No association of inducible nitric oxide synthase gene ( NOS2A) to multiple sclerosis.","date":"2003","source":"Journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/12736741","citation_count":14,"is_preprint":false},{"pmid":"36271438","id":"PMC_36271438","title":"Jatrorrhizine alleviates ulcerative colitis via regulating gut microbiota and NOS2 expression.","date":"2022","source":"Gut pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/36271438","citation_count":13,"is_preprint":false},{"pmid":"19635578","id":"PMC_19635578","title":"NO role of NOS2A susceptibility polymorphisms in rheumatoid arthritis.","date":"2009","source":"Nitric oxide : biology and chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19635578","citation_count":13,"is_preprint":false},{"pmid":"29752572","id":"PMC_29752572","title":"Propolis modulates NOS2/arginase-1 pathway in tropomyosin-induced experimental autoimmune uveitis.","date":"2018","source":"Inflammopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/29752572","citation_count":13,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":53094,"output_tokens":7639,"usd":0.136934,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":17238,"output_tokens":7103,"usd":0.131883,"stage2_stop_reason":"end_turn"},"total_usd":0.268817,"stage1_batch_id":"msgbatch_013a8chtv3AWyTqv4z4sEF4C","stage2_batch_id":"msgbatch_01AHsuW63vinsvuTgzmQ3n62","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1996,\n      \"finding\": \"The human NOS2 gene is transcriptionally activated by cytokines (TNFα, IL-1β, IFNγ), with multiple cytokine-responsive regions identified in the 5' flanking region at -3.8 to -5.8 kb, -5.8 to -7.0 kb, and -7.0 to -16 kb upstream of the transcription start site; the first 3.8 kb upstream showed no cytokine-inducible activity, in contrast to the murine macrophage NOS2 promoter.\",\n      \"method\": \"Nuclear run-on analysis; luciferase reporter constructs transfected into human liver epithelial cells (AKN-1); deletion analysis of NOS2 5' flanking region\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct promoter-reporter assays with deletion mapping and nuclear run-on in a defined cell system; multiple orthogonal methods in one study\",\n      \"pmids\": [\"8577713\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"NOS2-derived NO S-nitrosylates NF-κB p65 at a conserved cysteine in the Rel homology domain, inhibiting NF-κB-dependent gene transcription; nuclear levels of S-nitrosylated p65 correlate with decreased p50-p65 heterodimer DNA binding and reduced NOS2 promoter occupancy, establishing a negative feedback loop whereby NOS2 limits its own expression.\",\n      \"method\": \"S-nitrosylation detection in cytokine-stimulated respiratory epithelial cells and macrophages; site-directed mutagenesis of p65 cysteine; NF-κB reporter assays; chromatin immunoprecipitation (ChIP) of NOS2 promoter\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — mutagenesis of critical cysteine, ChIP for promoter occupancy, and functional reporter assays in multiple cell types in one study\",\n      \"pmids\": [\"17720813\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"LACC1 converts L-citrulline (the NOS2 reaction product) to L-ornithine and isocyanic acid, biochemically linking NOS2 to polyamine immunometabolism via ODC1; LACC1 phenotypes require upstream NOS2 and downstream ODC1 activity in inflammatory macrophages, demonstrated by genetic and chemical complementation.\",\n      \"method\": \"Biochemical enzyme assay; mouse genetic models (Lacc1-/-, Nos2-/-, Odc1 manipulation); bone marrow-derived macrophage infection with Salmonella; chemical complementation with L-ornithine\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — reconstituted enzyme activity, multiple knockout mouse models, chemical rescue, published in Nature with rigorous mechanistic validation\",\n      \"pmids\": [\"35978195\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"NOS2 expression and associated NO signaling causes degradation of DNMT1 protein via an NO/p38-MAPK/KAT5-dependent mechanism, leading to global DNA hypomethylation, LINE-1 retrotransposon activation, and epithelial transformation in human cell lines.\",\n      \"method\": \"NOS2 overexpression in human cell lines; DNMT1 protein stability assays; p38-MAPK inhibition; KAT5 manipulation; bisulfite sequencing for methylation; LINE-1 expression and DNA damage assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — mechanistic pathway (NO→p38-MAPK→KAT5→DNMT1 degradation→hypomethylation) validated with multiple orthogonal methods and inhibitor experiments in one study\",\n      \"pmids\": [\"35584114\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Induction and stability of human Th17 cells requires endogenous NOS2 activity within CD4+ T cells and the downstream canonical cGMP–cGK signaling pathway; NOS2 inhibition or cGMP-cGK blockade abolished de novo Th17 induction and selectively suppressed IL-17 production by established Th17 cells.\",\n      \"method\": \"NOS2 inhibition; cGMP-cGK pathway inhibition; differentiation of naive, memory, and tumor-infiltrating CD4+ T cells in vitro; cytokine measurement; patient-derived MDSCs and OvCa specimens\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — pharmacological and pathway inhibition experiments with human primary cells, multiple cell types, replicated across naive/memory/TIL subsets\",\n      \"pmids\": [\"23797095\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"In TLR4-activated microglia, Sur1-Trpm4 channels regulate Ca2+-sensitive calcineurin/NFAT signaling, which controls NOS2 transcription; inhibition or gene silencing of Sur1-Trpm4 reduces NFAT nuclear translocation and Nos2 upregulation, as confirmed by chromatin immunoprecipitation showing NFAT binding to the Nos2 promoter.\",\n      \"method\": \"Pharmacological inhibition of Sur1 (glibenclamide) and Trpm4 (9-phenanthrol); gene silencing of Abcc8 and Trpm4; calcium imaging; patch clamp; ChIP for NFAT at Nos2 promoter; qPCR; Griess assay for NO; primary microglia and N9 cell line; knockout mice (Abcc8-/-, Trpm4-/-)\",\n      \"journal\": \"Journal of neuroinflammation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — ChIP validation of NFAT-Nos2 promoter binding, electrophysiology, calcium imaging, genetic knockouts, and pharmacological confirmation in multiple systems\",\n      \"pmids\": [\"27246103\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"NO produced by NOS2 induces COX2 expression via TRAF2 activation (TNFα-dependent in MDA-MB-468 cells; TNFα-independent but ER-stress-dependent in MDA-MB-231 cells), while PGE2 (the COX2 product) induces NOS2 protein, establishing a feed-forward NOS2/COX2 crosstalk loop in triple-negative breast cancer cells.\",\n      \"method\": \"NOS2 and COX2 inhibition (aminoguanidine, aspirin/indomethacin); TRAF2 activity assays; TNFα neutralization; ER stress pathway analysis; xenograft tumor growth experiments; protein expression by Western blot\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — mechanistic pathway dissection with inhibitors, neutralizing antibodies, and in vivo xenograft validation across two TNBC cell lines\",\n      \"pmids\": [\"29087320\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"α-MSH inhibits LPS+IFNγ-induced NOS2 gene transcription in macrophages primarily by suppressing C/EBPβ (but not NF-κB) DNA-binding activity; deletion or mutation of the C/EBP box in the NOS2 promoter abolishes α-MSH's inhibitory effect, demonstrating that C/EBPβ is a required transcriptional activator of NOS2.\",\n      \"method\": \"Gel shift (EMSA) and supershift assays; NOS2 promoter-luciferase transfection with C/EBP box deletion/mutation constructs; RAW 264.7 macrophages\",\n      \"journal\": \"Kidney international\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — promoter mutagenesis combined with EMSA supershift identifying the specific transcription factor binding site required for NOS2 transcription\",\n      \"pmids\": [\"10844594\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Epigenetic regulation of Nos2 expression by the NLRC4 inflammasome requires caspase-1-mediated cleavage of PARP1 (ARTD1), which increases chromatin accessibility at NF-κB binding sites in the Nos2 promoter; caspase-1 acts downstream of NF-κB activation and is required for Nos2 transcription and NO-dependent macrophage resistance to Salmonella.\",\n      \"method\": \"Cytosolic flagellin stimulation; caspase-1 inhibition/knockout; NF-κB activation assays; PARP1 cleavage assays; chromatin accessibility assays; Salmonella infection of macrophages\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — mechanistic epistasis (caspase-1 downstream of NF-κB) established by genetic and pharmacological dissection with chromatin accessibility readout and functional infection outcome\",\n      \"pmids\": [\"28150715\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Rho GTPase signaling through ROCK suppresses NOS2 production downstream of promoter activity, at the mRNA and protein level; statin-mediated HMG-CoA reductase inhibition increases cytokine-dependent NOS2 promoter activity via geranylgeranylation-dependent prenylation events independent of the Rho/ROCK pathway.\",\n      \"method\": \"ROCK inhibitor (Y-27632); statin treatment; geranylgeranyl pyrophosphate rescue; NOS2 promoter-luciferase assays; mRNA and protein level measurements in human alveolar epithelial cells\",\n      \"journal\": \"American journal of physiology. Lung cellular and molecular physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — promoter assays combined with protein/mRNA level measurements and pharmacological pathway dissection in a single lab study\",\n      \"pmids\": [\"12169580\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"An S714P missense mutation in NOS2 from Dahl/Rapp salt-sensitive rats reduces NOS2 protein half-life (demonstrated by metabolic labeling) without affecting steady-state mRNA levels, decreasing nitrite production in a manner dependent on L-arginine concentration; a proteasomal post-translational degradation mechanism is implicated.\",\n      \"method\": \"Transient transfection of wild-type, S714P, and S714A NOS2 mutants into COS-7 cells; metabolic labeling to measure protein half-life; immunoblot; nitrite production assay with varying L-arginine concentrations\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro mutagenesis reconstitution with metabolic labeling establishing post-translational protein stability as the mechanism; single lab but rigorous methods\",\n      \"pmids\": [\"11509447\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"The pentanucleotide (CCTTT)n repeat within the NOS2A promoter functions as a transcriptional regulatory element; different repeat lengths confer different levels of IL-1β-inducible NOS2 promoter activity, with the 14-repeat allele showing the greatest induction in a luciferase reporter assay, and high-glucose conditions inhibit induction.\",\n      \"method\": \"Luciferase reporter gene assay with (CCTTT)n constructs of varying repeat length transfected into colonic carcinoma cells; IL-1β stimulation; high-glucose conditions\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct promoter-reporter functional assay; single lab, single method but with systematic allele series\",\n      \"pmids\": [\"10506586\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Tristetraprolin (TTP), encoded by Zfp36, directly binds AU-rich elements in the Nos2 3' UTR and suppresses Nos2 expression in intestinal epithelial cells; TTP knockout (Zfp36ΔIEC) mice show elevated Nos2 expression in the colonic epithelium and reduced susceptibility to DSS-induced colitis.\",\n      \"method\": \"Cre-lox conditional epithelial Zfp36 knockout mice; RNA-sequencing; TTP-Nos2 3'UTR interaction assay; DSS colitis model\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic knockout with cell-type-specific Cre, RNA-seq identification, direct 3'UTR binding assay, and in vivo functional phenotype\",\n      \"pmids\": [\"31595002\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"BRD4 regulates glycolysis-dependent stabilization of Nos2 mRNA in macrophages upon H. pylori infection; BRD4 is recruited to promoters of glycolytic genes (Slc2a1, Hk2) via HIF-1α to support glycolysis, and BRD4-mediated glycolysis stabilizes Nos2 mRNA for NO production needed to kill H. pylori; Brd4-deficient macrophages show impaired glycolysis, reduced iNOS expression, and increased bacterial colonization.\",\n      \"method\": \"Brd4 myeloid-specific conditional knockout (Brd4-CKO) mice; RNA sequencing; ChIP of BRD4 at glycolytic gene promoters; glycolysis assays; NO/killing assays; pyruvate rescue; in vivo H. pylori infection model\",\n      \"journal\": \"Cellular and molecular gastroenterology and hepatology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — conditional genetic knockout, ChIP, metabolic rescue, and in vivo infection model together establish the HIF-1α→BRD4→glycolysis→Nos2 mRNA stabilization pathway\",\n      \"pmids\": [\"37820788\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"NOS2 expression and NO production in the tumor microenvironment is induced by hypoxia, serum withdrawal, IFNγ, and exogenous NO in ER-negative breast cancer cells, consistent with a feed-forward regulation; NOS2 inhibition suppresses markers of aggressive phenotype (S100A8, IL-6, IL-8, TIMP-1), reduces cellular migration, increases chemosensitivity to Taxol, and suppresses tumor xenograft growth and brain metastasis.\",\n      \"method\": \"NOS2 inhibition in MDA-MB-231 cells; stimulation with hypoxia, serum withdrawal, IFNγ, and NO donors; marker expression assays; migration assay; Taxol chemoresistance assay; nude mouse xenograft and fat-pad-to-brain metastasis model\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple stimuli tested, pharmacological inhibition with defined phenotypic readouts, and in vivo xenograft/metastasis validation\",\n      \"pmids\": [\"24733928\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Mannan-induced NOS2 expression in macrophages drives IL-1α release from skin macrophages, which promotes IL-17 production by innate lymphoid cells and psoriatic arthritis pathogenesis; genetic deletion or pharmacological inhibition of Nos2 suppresses disease, and NOS2 expression is upregulated in monocytes from PsA patients.\",\n      \"method\": \"Nos2 knockout mice in mannan-induced psoriasis/PsA model; NOS inhibitor (L-NAME); IL-1α measurement; innate lymphoid cell IL-17 assay; patient monocyte NOS2 expression\",\n      \"journal\": \"Science advances\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic knockout and pharmacological inhibition establishing NOS2→IL-1α→IL-17 pathway in disease model, corroborated by human patient data\",\n      \"pmids\": [\"29774240\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Inherited autosomal recessive NOS2 deficiency (homozygous frameshift mutation producing a truncated, NO-inactive NOS2 protein) in a human patient was associated with fatal CMV infection, establishing that NOS2 is required for control of CMV in humans; the patient was otherwise resistant to other common pathogens, suggesting NOS2 is redundant for control of most infections.\",\n      \"method\": \"Whole-exome sequencing; experimental testing of mutant NOS2 alleles for NO production; functional assays of truncated NOS2 protein\",\n      \"journal\": \"The New England journal of medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — human genetic loss-of-function with experimental validation of NO-null truncated protein, unique clinical case establishing essential non-redundant role in CMV immunity\",\n      \"pmids\": [\"31995689\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"NOS2-derived NO downregulates tight junction protein ZO-1 expression at the transcriptional level in human lung epithelial cells; NOS2-/- mice show attenuated inflammatory response to bleomycin-induced injury with reduced NF-κB DNA-binding activity and a shift toward alternative macrophage activation.\",\n      \"method\": \"NOS2 inhibitor 1400W via osmotic pump; NOS2-/- mice; bleomycin instillation model; NF-κB DNA-binding activity assay; BAL analysis; ZO-1 mRNA and protein measurement; macrophage activation markers\",\n      \"journal\": \"Free radical biology & medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological inhibition and genetic knockout with mechanistic readouts in both in vivo and cell-based models, single lab\",\n      \"pmids\": [\"26526764\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"TLR4-mediated cardiomyocyte survival requires both MyD88 (the TLR4 adaptor) and NOS2; genetic deletion or pharmacological inhibition of NOS2 abolishes LPS-induced survival and functional rescue (Ca2+ transients, cell shortening) of cardiomyocytes under serum deprivation-induced apoptosis, placing NOS2 downstream of MyD88 in the TLR4 survival pathway.\",\n      \"method\": \"TLR4-/-, MyD88-/-, and pharmacological NOS2 inhibition in isolated cardiomyocytes; serum deprivation apoptosis model; TUNEL assay; DNA laddering; DNA-histone ELISA; Ca2+ transients; cell shortening measurements\",\n      \"journal\": \"American journal of physiology. Heart and circulatory physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis (TLR4→MyD88→NOS2) confirmed by multiple knockout lines with orthogonal apoptosis and function readouts\",\n      \"pmids\": [\"16648192\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"NOS2-derived NO mediates decreases in some cytochrome P450 catalytic activities (testosterone 6β-hydroxylase, 15α- and 16β-hydroxylase) during endotoxemia, as demonstrated by absence of these activity decreases in NOS2 knockout mice or aminoguanidine-treated mice; however, LPS-induced decreases in CYP2C29, CYP3A11 mRNA and CYP2E1, CYP2C-like, CYP3A-like protein levels occur independently of NOS2/NO.\",\n      \"method\": \"NOS2 knockout mice; aminoguanidine NOS inhibitor; LPS-induced endotoxemia model; cytochrome P450 mRNA and protein expression; testosterone hydroxylase activity assays\",\n      \"journal\": \"Molecular pharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic knockout and pharmacological inhibition with enzymatic activity assays distinguish NO-dependent from NO-independent P450 regulation\",\n      \"pmids\": [\"9687568\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"NOD1 (but not TLR4) is the dominant pathway for NOS2 induction in vascular smooth muscle cells; NOD1-mediated NOS2 induction requires Rip2 kinase (inhibited by PP2) whereas TLR4-mediated macrophage NOS2 induction requires caspase activity and PKC; both pathways converge on NF-κB and MAPK signaling.\",\n      \"method\": \"Pharmacological inhibitors (SC-514 for NF-κB, SB203580/PD98059 for MAPK, z-VAD-fmk for caspase, Gö6976 for PKC, PP2 for Rip2); NOD1 agonist FK565; LPS for TLR4; NOS2 protein expression and NO production in vascular smooth muscle cells vs. macrophages\",\n      \"journal\": \"British journal of pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — systematic pharmacological pathway dissection in two cell types, single lab study\",\n      \"pmids\": [\"20649597\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"IL-17 intensifies IFNγ-induced NOS2 upregulation in RAW 264.7 macrophages by further activating STAT1 phosphorylation (Y701) and NF-κB nuclear translocation; IL-17 enhances p38 MAPK phosphorylation and limits ERK1/2 phosphorylation, thereby augmenting NF-κB pathway activity and NOS2 transcription. ChIP confirmed enhanced STAT1 and NF-κB binding to the NOS2 promoter.\",\n      \"method\": \"Western blot for STAT1, NF-κB, p38 MAPK, ERK1/2 phosphorylation; ChIP assay for STAT1 and NF-κB at NOS2 promoter; STAT1 and NF-κB inhibitors; colorimetric NO assay; qPCR\",\n      \"journal\": \"International journal of molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus inhibitor experiments establish transcription factor contributions to NOS2 promoter; single lab\",\n      \"pmids\": [\"26677135\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Manganese potentiates LPS-induced NOS2 expression in C6 glioma cells through mitochondrial ROS production, which activates NF-κB (via NIK-mediated IκBα phosphorylation); overexpression of dominant-negative IκBα or NIK mutant, or scavenging mitochondrial ROS with MitoQ, attenuates Mn-enhanced NOS2 expression.\",\n      \"method\": \"Overexpression of mutant IκBα (S32/36A) and dominant-negative NIK; MitoQ mitochondrial antioxidant; gel shift for NF-κB p65/p50; mitochondrial membrane potential and calcium assays; ROS measurement; NOS2 protein and NO assays\",\n      \"journal\": \"Brain research. Molecular brain research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — dominant-negative constructs and organelle-specific antioxidant establish the mitochondrial ROS→NIK→NF-κB→NOS2 pathway; single lab\",\n      \"pmids\": [\"15010209\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"DNA-based probes targeting phagosomal NO demonstrate that single-stranded RNA of bacterial origin acts as a PAMP that activates NOS2 in microglia phagosomes by engaging TLR-7; this PAMP-TLR7 interaction triggers rapid phagosomal NOS2 activity, mapped in live zebrafish brains.\",\n      \"method\": \"DNA-based ratiometric NO probes delivered to phagosomes and endosomes; live zebrafish brain imaging; TLR-7 activation; microglia phagosomal NO measurement\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — novel direct real-time imaging of NOS2 activity in phagosomes linked to specific PAMP-TLR7 interaction; single study, technically innovative\",\n      \"pmids\": [\"32554491\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"NOS2 expression is restricted to scattered neurons in specific brain regions (piriform and entorhinal cortex, amygdala, thalamus, hypothalamus, dentate gyrus, cerebellum) in the healthy brain, but inflammation (intracerebral LPS + IFNγ) triggers transient NOS2 expression in microglia rather than neurons; NOS2 expression is rarely detected in microglia under non-inflammatory conditions.\",\n      \"method\": \"Transgenic mouse expressing tdTomato and CRE recombinase under Nos2 regulatory regions (lineage tracing); immunohistochemistry; intracerebral LPS + IFNγ injection\",\n      \"journal\": \"Glia\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — purpose-built lineage-tracing transgenic mouse providing reliable cell-type-specific NOS2 expression mapping under basal and inflammatory conditions\",\n      \"pmids\": [\"24615726\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"NOS2 promotes apoptosis in acute cardiac allograft rejection via p53-dependent mechanisms; NOS2-deficient recipients show reduced p53 transcript levels, increased Bcl-2/Bax ratio, decreased Bcl-Xl, lower caspase-1 and -3 activity, and fewer TUNEL-positive nuclei; Fas/FasL and TNFα/TNFR1 pathways are not altered by NOS2 deficiency.\",\n      \"method\": \"NOS2 knockout recipient mice in heterotopic cardiac transplant model; TUNEL assay; antinucleosome ELISA; 32P-RT-PCR for caspase-1/-3, p53, Bcl-2, Bax, Bcl-Xl; DEVD-pNA caspase-3 activity; PARP cleavage\",\n      \"journal\": \"Circulation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal apoptosis assays combined with genetic epistasis in knockout mice establishing NOS2→p53→Bax/Bcl-2 apoptotic pathway\",\n      \"pmids\": [\"9989972\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"NOS2 (inducible nitric oxide synthase) is a cytokine- and pathogen-inducible enzyme that synthesizes NO from L-arginine (with L-citrulline as co-product); its transcription is controlled by multiple upstream regulators including NF-κB, STAT1, C/EBPβ, NFAT (via Sur1-Trpm4/Ca2+ signaling), caspase-1/PARP1 epigenetic remodeling, BRD4-mediated glycolysis, and post-transcriptional suppression by TTP binding to Nos2 3'UTR, while NOS2-derived NO exerts negative feedback by S-nitrosylating NF-κB p65; the enzyme functions in inflammatory macrophages upstream of LACC1 (converting its citrulline product to ornithine for polyamine metabolism), promotes Th17 differentiation via cGMP-cGK signaling, drives apoptosis in tissue rejection via p53 activation, mediates epigenetic transformation through DNMT1 degradation via p38-MAPK/KAT5, regulates cytochrome P450 catalytic activities, and is essential for anti-CMV immunity in humans.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"NOS2 (inducible nitric oxide synthase) is a cytokine- and pathogen-inducible enzyme that synthesizes nitric oxide (NO) from L-arginine to drive inflammatory, immunometabolic, and tissue-remodeling programs [#0, #2]. Its expression is normally absent or low and is induced transcriptionally by pro-inflammatory cytokines (TNFα, IL-1β, IFNγ) acting through distal 5' regulatory regions of the human gene [#0], with C/EBPβ identified as a required promoter-binding activator [#7] and STAT1 and NF-κB cooperating to amplify induction, for example when IL-17 augments IFNγ signaling [#21]. Diverse upstream inputs converge on this control: NOD1/Rip2 and TLR4 signaling [#20], TLR7-sensed bacterial RNA in microglial phagosomes [#23], NLRC4/caspase-1-mediated PARP1 cleavage that opens chromatin at NF-κB sites [#8], Sur1-Trpm4/Ca2+/calcineurin-NFAT signaling [#5], and HIF-1α/BRD4-driven glycolysis that stabilizes Nos2 mRNA [#13]; conversely, tristetraprolin binds AU-rich elements in the Nos2 3'UTR to suppress its expression [#12], and NOS2-derived NO S-nitrosylates NF-κB p65 to reduce NOS2 promoter occupancy, forming a negative-feedback loop [#1]. Downstream, NOS2 acts as a hub of inflammatory effector functions: its L-citrulline product is channeled by LACC1 to ornithine and polyamine immunometabolism via ODC1 in macrophages [#2], its NO supports antibacterial killing and Th17 induction through cGMP-cGK signaling [#4, #13], and it links to a feed-forward NOS2/COX2 loop and aggressive phenotypes in breast cancer [#6, #14]. NO further drives p53-dependent apoptosis in cardiac allograft rejection [#25] and NO/p38-MAPK/KAT5-mediated DNMT1 degradation causing DNA hypomethylation and epithelial transformation [#3]. Inherited autosomal recessive NOS2 deficiency in humans causes fatal CMV infection while sparing control of most other pathogens, defining a non-redundant role in anti-CMV immunity [#16].\",\n  \"teleology\": [\n    {\n      \"year\": 1996,\n      \"claim\": \"Established that the human NOS2 gene is transcriptionally inducible by inflammatory cytokines and mapped the responsive elements to distal upstream regions, distinguishing human regulation from the murine macrophage promoter.\",\n      \"evidence\": \"Nuclear run-on and deletion-mapped luciferase reporters in human liver epithelial cells stimulated with TNFα/IL-1β/IFNγ\",\n      \"pmids\": [\"8577713\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not identify the specific transcription factors binding the distal regions\", \"Functional relevance in immune cell types not addressed\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Defined a downstream consequence of NOS2 activity by showing NO selectively suppresses specific cytochrome P450 catalytic activities during endotoxemia, separating NO-dependent from NO-independent P450 regulation.\",\n      \"evidence\": \"NOS2 knockout mice and aminoguanidine in an LPS endotoxemia model with P450 activity and expression assays\",\n      \"pmids\": [\"9687568\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular mechanism of NO action on P450 enzymes not resolved\", \"Limited to a subset of P450 isoforms\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Identified a cis-acting polymorphic element by showing the promoter (CCTTT)n pentanucleotide repeat modulates IL-1β-inducible NOS2 transcription in an allele-length-dependent manner.\",\n      \"evidence\": \"Luciferase reporter assays with varying (CCTTT)n repeat constructs in colonic carcinoma cells\",\n      \"pmids\": [\"10506586\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single cell line, single reporter method\", \"Trans-acting factor binding the repeat not identified\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Identified C/EBPβ as a required transcriptional activator of NOS2 and a target of anti-inflammatory α-MSH, defining a specific factor distinct from NF-κB.\",\n      \"evidence\": \"EMSA/supershift and promoter-luciferase assays with C/EBP box deletion/mutation in RAW 264.7 macrophages\",\n      \"pmids\": [\"10844594\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How α-MSH signaling reaches C/EBPβ DNA binding not detailed\", \"Macrophage cell line only\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Demonstrated post-translational control of NOS2 abundance by showing an S714P mutation shortens protein half-life without affecting mRNA, implicating proteasomal degradation.\",\n      \"evidence\": \"Mutant NOS2 transfection in COS-7 cells with metabolic labeling and nitrite assays\",\n      \"pmids\": [\"11509447\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific degradation machinery (E3 ligase) not identified\", \"Findings derived from a rat salt-sensitive allele in a heterologous cell line\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Connected NOS2 to apoptotic tissue injury by showing NO drives p53-dependent apoptosis during cardiac allograft rejection independently of Fas and TNF pathways.\",\n      \"evidence\": \"NOS2 knockout recipients in a heterotopic cardiac transplant model with multiple apoptosis readouts\",\n      \"pmids\": [\"9989972\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct molecular link between NO and p53 induction not defined\", \"Cell type executing apoptosis not specified\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Showed NOS2 induction can be amplified by mitochondrial ROS via the NIK/NF-κB axis, broadening the upstream signals controlling NOS2.\",\n      \"evidence\": \"Dominant-negative IκBα/NIK and mitochondrial antioxidant MitoQ with NF-κB gel shifts in C6 glioma cells\",\n      \"pmids\": [\"15010209\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single cell line and stimulus (manganese)\", \"Physiological relevance beyond metal exposure unclear\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Placed NOS2 downstream of TLR4/MyD88 as a pro-survival effector in cardiomyocytes, expanding NOS2 function beyond cytotoxic inflammation.\",\n      \"evidence\": \"TLR4-/-, MyD88-/- and NOS2 inhibition in isolated cardiomyocytes under serum deprivation apoptosis\",\n      \"pmids\": [\"16648192\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream survival signaling from NO not mapped\", \"Context dependence of pro-survival vs pro-apoptotic NO unresolved\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Revealed a negative-feedback mechanism by which NOS2-derived NO S-nitrosylates NF-κB p65 to reduce NOS2 promoter occupancy, allowing the enzyme to limit its own induction.\",\n      \"evidence\": \"p65 cysteine mutagenesis, S-nitrosylation detection, NF-κB reporters and NOS2 promoter ChIP in epithelial cells and macrophages\",\n      \"pmids\": [\"17720813\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Quantitative contribution of feedback to physiological NO output not established\", \"Other S-nitrosylation targets in the pathway not assessed\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Distinguished cell-type-specific upstream pathways, identifying NOD1/Rip2 as dominant for NOS2 induction in vascular smooth muscle versus TLR4/caspase/PKC in macrophages, both converging on NF-κB/MAPK.\",\n      \"evidence\": \"Systematic pharmacological inhibitor dissection in vascular smooth muscle cells versus macrophages\",\n      \"pmids\": [\"20649597\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Inhibitor-based, no genetic confirmation\", \"Single lab, two cell types\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Defined an effector role for NOS2 in adaptive immunity by showing endogenous NOS2 and downstream cGMP-cGK signaling are required for human Th17 induction and stability.\",\n      \"evidence\": \"NOS2 and cGMP-cGK pathway inhibition in human naive, memory, and tumor-infiltrating CD4+ T cells\",\n      \"pmids\": [\"23797095\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular targets of cGK driving IL-17 not identified\", \"Mainly pharmacological inhibition\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Mapped basal versus inflammatory NOS2-expressing cell types in brain, showing scattered neuronal expression at baseline and inducible microglial expression under inflammation.\",\n      \"evidence\": \"Nos2 promoter-driven lineage-tracing transgenic mice with immunohistochemistry under basal and LPS+IFNγ conditions\",\n      \"pmids\": [\"24615726\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional role of basal neuronal NOS2 not addressed\", \"Mouse data only\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Established NOS2 as a driver of aggressive tumor phenotype, with NO induced by hypoxia/IFNγ and feed-forward NO promoting migration, chemoresistance, and metastasis in ER-negative breast cancer.\",\n      \"evidence\": \"NOS2 inhibition with multiple stimuli and in vivo xenograft/brain metastasis models in MDA-MB-231 cells\",\n      \"pmids\": [\"24733928\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct molecular targets of NO driving each phenotype not fully resolved\", \"Cell-line-restricted models\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Showed NO regulates epithelial barrier integrity and inflammatory tone by transcriptionally downregulating ZO-1 and shaping macrophage polarization and NF-κB activity in lung injury.\",\n      \"evidence\": \"NOS2 inhibitor and NOS2-/- mice in a bleomycin lung injury model with ZO-1 and NF-κB readouts\",\n      \"pmids\": [\"26526764\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism linking NO to ZO-1 transcription unresolved\", \"Single lab\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Showed IL-17 cooperates with IFNγ to intensify NOS2 transcription by enhancing STAT1 phosphorylation and NF-κB binding at the NOS2 promoter.\",\n      \"evidence\": \"Phospho-signaling Western blots, NOS2 promoter ChIP, and inhibitors in RAW 264.7 macrophages\",\n      \"pmids\": [\"26677135\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single cell line\", \"Relative contributions of STAT1 vs NF-κB not quantified\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Identified Sur1-Trpm4/Ca2+-calcineurin-NFAT signaling as an upstream controller of Nos2 transcription in TLR4-activated microglia.\",\n      \"evidence\": \"Pharmacology, gene silencing, calcium imaging, patch clamp, knockout mice, and NFAT ChIP at the Nos2 promoter\",\n      \"pmids\": [\"27246103\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Interaction with canonical NF-κB control not integrated\", \"Restricted to microglial context\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Defined a feed-forward NOS2/COX2 crosstalk loop in triple-negative breast cancer, with NO inducing COX2 via TRAF2 and PGE2 inducing NOS2.\",\n      \"evidence\": \"Enzyme inhibitors, TRAF2 assays, ER-stress analysis, and xenografts across two TNBC cell lines\",\n      \"pmids\": [\"29087320\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Generalizability beyond TNBC cell lines unclear\", \"Quantitative loop dynamics not modeled\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Uncovered an epigenetic mechanism of NOS2 induction in which NLRC4/caspase-1-mediated PARP1 cleavage increases chromatin accessibility at NF-κB sites in the Nos2 promoter, placing caspase-1 downstream of NF-κB.\",\n      \"evidence\": \"Cytosolic flagellin stimulation, caspase-1 perturbation, PARP1 cleavage and chromatin accessibility assays with Salmonella infection\",\n      \"pmids\": [\"28150715\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct demonstration that PARP1 cleavage product drives accessibility not fully isolated\", \"Limited to inflammasome-activating contexts\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Linked macrophage NOS2 to autoinflammatory disease by showing NOS2 drives IL-1α release and downstream IL-17 from innate lymphoid cells in psoriatic arthritis.\",\n      \"evidence\": \"Nos2 knockout mice and NOS inhibition in a mannan-induced PsA model corroborated by patient monocyte data\",\n      \"pmids\": [\"29774240\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism connecting NO to IL-1α release not defined\", \"Model-specific induction\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Identified post-transcriptional restraint of NOS2 by showing tristetraprolin binds the Nos2 3'UTR to suppress epithelial expression, tuning colitis susceptibility.\",\n      \"evidence\": \"Epithelial-specific Zfp36 knockout mice, RNA-seq, 3'UTR binding assay, and DSS colitis model\",\n      \"pmids\": [\"31595002\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Interplay with transcriptional induction not quantified\", \"Restricted to intestinal epithelium\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Defined the essential, non-redundant role of NOS2 in human anti-CMV immunity through a patient with inherited NO-null NOS2 deficiency and fatal CMV infection.\",\n      \"evidence\": \"Whole-exome sequencing and functional NO-production testing of a truncated mutant NOS2 allele\",\n      \"pmids\": [\"31995689\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Single patient\", \"Cellular mechanism by which NO controls CMV not defined\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Demonstrated phagosomal NOS2 activation in microglia triggered by bacterial single-stranded RNA engaging TLR7, using real-time NO imaging.\",\n      \"evidence\": \"DNA-based ratiometric NO probes in live zebrafish brain phagosomes with TLR7 activation\",\n      \"pmids\": [\"32554491\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanistic coupling of TLR7 to phagosomal NOS2 not detailed\", \"Single technically novel study\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Connected NOS2 enzymatic output to immunometabolism by showing LACC1 converts the citrulline product to ornithine feeding ODC1-dependent polyamine metabolism in inflammatory macrophages.\",\n      \"evidence\": \"Reconstituted enzyme assay, multiple knockout mice (Lacc1, Nos2, Odc1), Salmonella infection, and ornithine chemical rescue\",\n      \"pmids\": [\"35978195\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Flux contribution relative to other citrulline fates not quantified\", \"Human in vivo relevance not addressed\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Revealed an oncogenic epigenetic mechanism in which NOS2/NO drives DNMT1 degradation via p38-MAPK/KAT5, causing DNA hypomethylation, LINE-1 activation, and epithelial transformation.\",\n      \"evidence\": \"NOS2 overexpression, DNMT1 stability assays, p38/KAT5 manipulation, bisulfite sequencing, and LINE-1 readouts in human cell lines\",\n      \"pmids\": [\"35584114\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo tumorigenesis validation limited\", \"Step linking NO to p38-MAPK activation not detailed\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Established a metabolic-epigenetic axis controlling NOS2 mRNA stability, in which HIF-1α-recruited BRD4 supports glycolysis that stabilizes Nos2 mRNA for antibacterial NO production.\",\n      \"evidence\": \"Myeloid Brd4 conditional knockout mice, RNA-seq, BRD4 ChIP at glycolytic genes, glycolysis/NO assays, pyruvate rescue, and in vivo H. pylori infection\",\n      \"pmids\": [\"37820788\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct RNA-stabilizing factor linking glycolysis to Nos2 mRNA not identified\", \"Restricted to H. pylori macrophage context\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the many parallel transcriptional, post-transcriptional, metabolic, and post-translational inputs are quantitatively integrated to set NOS2 output in a given cell type, and how NO output is matched to specific effector outcomes, remains unresolved.\",\n      \"evidence\": \"No single study integrates the multiple convergent regulatory layers captured in the timeline\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No unified quantitative model of NOS2 regulation across cell types\", \"Cell-type-specific determinants of pro-survival vs cytotoxic vs oncogenic NO not defined\", \"Structural and catalytic regulation of the human enzyme not addressed in this corpus\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016491\", \"supporting_discovery_ids\": [2, 16]},\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [0, 16]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [10, 23]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [2, 4, 13, 16]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 1, 7, 8, 5]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [2, 13]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [25, 18]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [3, 8]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [18, 20]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"LACC1\", \"RELA\", \"CEBPB\", \"STAT1\", \"PARP1\", \"DNMT1\", \"TRAF2\", \"ZFP36\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}